Paikkakohtaisen annostavoitten käyttö sädehoidon suunnittelussa by Voutilainen, Arttu
Spatial Objectives in Radiation Therapy
Treatment Planning
Arttu Voutilainen
School of Science
Thesis submitted for examination for the degree of Master of
Science in Technology.
Espoo 31.5.2016
Thesis supervisor:
Prof. Harri Ehtamo
Thesis advisor:
D.Sc. (Tech.) Ville Pietilä
aalto university
school of science
abstract of the
master’s thesis
Author: Arttu Voutilainen
Title: Spatial Objectives in Radiation Therapy Treatment Planning
Date: 31.5.2016 Language: English Number of pages: 7+53
Department Mathematics and Systems Analysis
Professorship: Systems and Operations Research
Supervisor: Prof. Harri Ehtamo
Advisor: D.Sc. (Tech.) Ville Pietilä
Modern intensity modulated radiation therapy allows a precise control over the
dose absorbed by the patient’s body. This requires a large number of parameters
to define a treatment. Thus instead of specifying the parameters the treatment
planner specifies the wanted outcome, after which an optimization algorithm aims to
create a treatment plan that satisfies the objectives set by the planner. A common
objective type is a dose-volume objective that indicates an upper or a lower limit
for dose level for a certain volume of a critical organ, tumor or other structure.
Objectives based on biological tissue responses can also be used. However, these
objectives do not offer control over the exact 3D distribution of the dose.
This work introduces a new objective type, a spatial objective, to be used in
radiation therapy treatment planning, and evaluates its usage in a realistic use case.
The objective is implemented on top of the Eclipse Treatment Planning System
(Varian Medical Systems, Inc.). A spatial objective sets an upper or a lower limit
for the dose in all voxels inside a patient’s body. The limit is set for each voxel
individually, allowing the planner an exact control over the spatial features of the
dose distribution.
In this work it is shown that the spatial objective can be used to direct the optimizer
to a physically realistic dose distribution. Spatial objectives can also be utilized
to perform plan conversion, i.e., to convert a treatment plan from one treatment
machine to another, possibly dosimetrically inequivalent machine. This kind of
conversion is required for example if the original treatment machine breaks down.
A conversion utilizing the spatial objectives is shown to produce plans that are of
comparable or superior quality than those produced by the current tool used in
Eclipse.
The results of this thesis can be used to improve the radiation therapy treatment
planning and the treatments received by the patients.
Keywords: radiation therapy, optimization, objective, gradient search, treatment
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Moderni intensiteettimoduloitu sädehoito mahdollistaa potilaaseen kohdistuvan
säteilyannoksen tarkan hallinan. Samalla hoidon määrittämiseen tarvittavien pa-
rametrien määrä kasvaa varsin suureksi. Yksittäisten parametrien määrittelemi-
sen sijaan hoidon suunnittelussa määritellään haluttu lopputulos, jonka jälkeen
optimointialgoritmi pyrkii luomaan hoitosuunnitelman, joka toteuttaa annetut
tavoitteet. Tyypillisesti suunnittelussa käytetään annos-tilavuus-tavoitteita, jotka
osoittavat ylä- tai alarajan annokselle tietyssä osassa tärkeän elimen, kasvaimen
tai muun rakenteen tilavuutta. Kudoksen biologisiin ominaisuuksiin perustuvia
tavoitteita on myös mahdollista käyttää. Nämä työkalut eivät kuitenkaan tarjoa
mahdollisuutta hallita annosjakauman kolmiuloitteista ominaisuuksia.
Tässä työssä esitellään uusi tavoitetyyppi, paikkakohtainen annostavoite, ja arvioi-
daan sen käyttöä realistisessa käyttötapauksessa. Työtä varten paikkakohtainen
annostavoite toteutettiin Eclipse-hoidonsuunnitteluohjelman (Varian Medical Sys-
tems, Inc) yhteyteen. Paikkakohtaisessa annostavoitteesa potilaan kehon jokaiseen
tilavuusalkioon voidaan määrätä säteilyannos, jota ei tule ylittää tai alittaa. Annos
määrätään jokaiseen tilavuusalkioon erikseen, mikä mahdollistaa annosjakauman
kolmiuloitteisten piirteiden hallinnan.
Työssä näytetään, että paikkakohtaisia annostavoitteita käyttäen optimointialgorit-
min voi ohjata kohti haluttua, fysikaalisesti realistista annosjakaumaa. Tavoitteita
voi käyttää myös yhdelle hoitokoneelle suunnitellun hoidon muuntamiseen toi-
selle, dosimetrisesti erilaiselle hoitokoneelle sopivaksi. Muuntaminen on tarpeen
esimerkiksi alkuperäisen hoitokoneen rikkoutuessa. Paikkakohtaisia annostavoit-
teita hyödyntävän muunnoksen näytetään tuottavan samanveroisia tai parempia
hoitosuunnitelmia Eclipsen nykyiseen muuntotyökaluun verratuna.
Tämän työn tuloksia hyödyntäen voidaan kehittää sädehoitojen suunnittelua ja
parantaa potilaiden saamaa hoitoa.
Avainsanat: sädehoito, optimointi, optimointitavoite, gradienttihaku, hoidon
suunnittelu
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1 Introduction
Cancer is a major problem in today’s world. In 2012, there were 14 million cancer
incidences and 8 million cancer deaths (Stewart and Wild [2014]) worldwide, with
cancer being the second most common cause of death after cardiovascular diseases
(17 million deaths in 2013) (Naghavi et al. [2015]). In the United States, it has been
estimated that about 40% of the population will be diagnosed with cancer during
their lifetime (Howlader et al. [2015]). More than half of the patients will receive
radiation therapy as part of their treatment (Halperin et al. [2004]).
The aim of radiation therapy is to destroy or harm the cancer by killing cancer
cells while minimizing adverse effects on healthy tissue. Radiation therapy planning
can be viewed as multi-objective optimization problem, where the objectives are to
maximize the probability of cure and to minimize the probability of adverse effects.
Radiation therapy can be external or internal. In internal radiation therapy the
radiation source is injected into the patient, while in external radiation therapy the
radiation comes from outside of the patient’s body. Often the ionizing radiation
beam from an external source is delivered by photons, but also electrons, protons,
neutrons and ions are possible (Hoppe et al. [1979], Paganetti and Bortfeld [2006],
Orecchia et al. [1998]). For the purpose of this work, only external photon beam
treatments are considered, but the same principles should apply to other modalities
as well.
An external radiation therapy treatment plan consists of many parameters such as
the number of beams, their geometric setup and the intensities of the beams. With
the advent of sophisticated beam-shaping devices such as the multi-leaf collimator
that allows intensity modulation within each beam, the number of parameters has
dramatically increased. An example is the intensity modulated radiation therapy
(IMRT) where each beam is divided into a grid of beamlets, the intensity of which can
be individually chosen. The increased number of parameters has lead to a transition
to inverse planning, where the treatment planner specifies the wanted outcome and a
computer program calculates the parameters that come closest to having the desired
results.
The inverse planning problem cannot be solved analytically, but numerical optimiza-
tion methods can be used to find an approximate solution (Bortfeld et al. [1992]).
Current optimization methods for inverse planning use mainly dose-volume objectives
that specify the upper or lower bounds for dose in some volume of a specific organ
or other structure. Usually an upper dose objective is used for organs at risk, while
both an upper and a lower dose objectives are specified for the tumor.
While dose-volume objectives work well in most cases, sometimes an objective
containing spatial information can be useful. The planned dose can be visualized
as dose-volume histograms and through 2D projections of the 3D dose distribution.
Dose-volume objectives have a 1-to-1 correspondence with histograms, allowing the
treatment planner to investigate if the objectives were achieved, and possibly tune
2the objectives for better results. In some cases the planner might want to control
the dose distribution directly, for example to decide on a trade-off between a dose to
the tumor and a dose to a critical organ intersecting with the tumor. There is no
direct mapping from dose-volume objectives to the dose distribution, and in order to
control the spatial features the planner needs to create artificial control structures
used only for the optimization. An objective able to convey spatial information to
the optimizer would give the planner more direct control over the dose distribution.
Another potential use case for the spatial objective would be the case where a
treatment plan needs to be converted to a different machine (plan conversion). Each
plan is designed specifically for some treatment machine. If the machine breaks
down, the plan has to be converted to another machine to allow treating the patient
while the broken machine is being repaired. The secondary machine may not be
dosimetrically equivalent to the original machine, in which case the conversion is not
trivial.
In the plan conversion case, the source plan reflects the clinical aims of the planner.
Dose-volume objectives can be used to replicate the dose-volume histograms in the
new plan, but in this case the spatial information is lost. Hence, the new plan may
not exhibit the spatial features intended by the planner. For example, a high-dose
region might move from inside the tumor closer to some critical organ resulting in a
higher possibility for irradiating the organ due to organ movement and imperfections
in patient positioning. The use of dose-volume objectives requires the planner to
select the important organs that are considered in the conversion. Utilizing a spatial
objective could help to automate the process.
The current planning paradigm aims at a homogeneous dose to the tumor. In reality
the tumors are not homogeneous, so one might want to use a heterogeneous dose
based on the biological properties of the tumor. This dose painting method suggested
by Bentzen [2005] would also benefit from an easy way to specify different dose levels
to different parts of the tumor.
To tackle these issues, this thesis reviews the idea of using spatial dose information
as an optimization objective and investigates how it should be used to improve the
optimization results. The use of spatial objectives in the plan conversion use case is
also analyzed.
The thesis is structured as follows. In Section 2, the theory and practice of radiation
therapy is reviewed. Section 3 discusses plan quality metrics that can be used to asses
the quality of the treatment plans. The current optimization methods are described
in Section 4. In Section 5 the spatial objective is presented and studied. Section 6
analyzes the plan conversion use case, and Section 7 presents the conclusions.
This thesis is written at Varian Medical Systems Finland, Helsinki. All of the test
data is provided by Varian and a modified version of Varian’s Eclipse Treatment
Planning System is used to perform the tests.
32 Theory and practice of radiation therapy
Normally the lifetime of a cell, including its division and death, is regulated. This
means that a cell divides only when new cells are needed and dies through apoptosis
when it is no longer needed. If these regulations cease to work, the cell starts to
divide in an uncontrolled manner and fails to self-eliminate, which results in a tumor
being created. (Hall and Giaccia [2006])
If the tumor grows by displacing the healthy tissues next to it, it is called benign. If
treatment is needed, such tumor can often be surgically removed. Cancer tumors
are always malignant, meaning that the tumor grows by invading adjacent tissues
(Hall and Giaccia [2006]). Surgical removal of a malignant tumor is complicated
and sometimes impossible, as removing the tumor would also necessitate removal of
healthy tissue. There might also be microscopic metastasis (cancer cells not directly
connected to the primary tumor), the removal of which is difficult or impossible
through surgery. The unattended microscopic metastasis can lead to the recurrence
of the tumor (Moss and Cox [1994]). For these reasons there is need for a cure which
kills cancerous cells but spares the healthy cells.
2.1 Biological background of radiation therapy
Radiation therapy works mainly by using ionizing radiation - photons (X-rays),
electrons, protons, neutrons or ions - to damage the cells’ DNA. The radiation can
damage DNA either directly or indirectly (by creating radical ions that react with
the DNA molecules). A single strand break is likely to be repaired by the cell, as
well as multiple single strand breaks when they are spatially far apart. In case there
are two breaks opposite to each other or in close proximity, the probability of a
double strand break is high. Double strand breaks are believed to be the main reason
for radiation-induced cell death (Hall and Giaccia [2006]). Healthy cells are better
at repairing damage than cancer cells. This combined with other effects (such as
reoxygenation of tumor cells and reassortment of cells withing the cell cycle) leads to
the tumor cells being more sensitive to radiation when the radiation dose is delivered
in small fractions over longer period of time instead of as one large fraction at once.
Nevertheless, the normal tissue may be unable to repair all damage to the DNA
strand or they may make erroneous corrections, leading to complications.
The probability that a certain dose of radiation kills the cancer cells is called the
tumor control probability (𝑇𝐶𝑃 ) (Hasson et al. [2013]). Likewise, the probability of
complications in healthy tissue is known as the normal tissue complication probability
(NTCP) (Michalski et al. [2013]). The aim is to have a dose for which the TCP
is high while the NTCP stays low. The ratio of TCP and NTCP is known as
the therapeutic ratio. The therapeutic ratio, TCP, and NTCP are schematically
illustrated in Figure 1.
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Figure 1 – The therapeutic ratio is a function of the tumor control probability and
the normal tissue complication probability. (a) Increasing the dose leads to a higher
TCP but also to a higher NTCP. (b) Improvements in the treatment separate the gap
between the TCP and the NTCP.
Improving the therapeutic ratio is the main focus of the radiation therapy research.
The fractionation pattern (how much dose per fraction, how many fractions and
how frequently) affects the therapeutic ratio. Drugs and heating the tumor can be
used to increase cancer cells’ sensitivity to radiation (Halperin et al. [2004]). The
distribution of the dose also has an effect on the therapeutic ratio. Increasing the
dose the tumor receives increases the TCP, and reducing the dose that is absorbed
by the normal tissues decreases the NTCP.
2.2 Structure delineation
For the purpose of treatment planning it is important to have models of the tumor
and healthy tissues. Before a treatment plan (later referred to as plan) can be
created, the patient must be scanned with a CT or MRI scanner to produce a three
dimensional (3D) image of the body. The scanners take 2D-images, called slices, that
can then be combined to form the 3D representation. The resolution of the images
as well as the spacing between the slices control the accuracy of the 3D model. Using
the 3D data, the volumes of the tumor and organs at risk (OAR) can be defined.
These defined volumes are called structures.
For treatment planning it is customary to define multiple tumor volumes with the
gross tumor volume (GTV) being the known tumor volume, and the clinical target
volume (CTV) encompassing the GTV and the subclinical malignant disease. The
planning target volume (PTV) is a volume created by extending the CTV with a
margin corresponding to the uncertainties that come from the treatment machine
parameters, tumor movement, and patient setup (Grégoire and Mackie [2011]). There
can be multiple tumors leading to multiple PTVs. Multiple PTVs can also be used
to implement simultaneous integrated boost strategy, where some parts of the tumor
receive a higher amount of dose. The PTV is also referred to as the target.
52.3 Treatment machines
Modern radiation therapy treatment machines consist of three main parts: linear
accelerator (linac) which produces the radiation, rotating gantry through which
the radiation beam is projected and treatment couch on which the patient lies. A
modern radiation therapy machine is shown in Figure 2. The intersection of gantry’s
rotational axis with the beam axes is called the isocenter. The couch also has a
rotational axis that goes through the isocenter. Using the rotations of the gantry
and the couch radiation can be delivered in principle from any solid angle around
the isocenter. Often all beams are chosen to be co-planar, in which case only the
gantry rotates during treatment.
Figure 2 – A modern radiation therapy treatment machine. Image courtesy of Varian
Medical Systems, Inc.
To control the shape of the beam, a beam limiting device can be used. Current
machines usually include a multileaf collimator (see Figure 3) that is able to produce
very detailed shapes for the beam (Halperin et al. [2004]). An MLC consists of tens
of opposing pairs of leaves that are able to move independently of each other. The
leaves are thick enough not to let (almost) any radiation through, limiting the beam
to the gaps between the leaves.
The linear accelerators are often capable of producing radiation of different energies
(Halperin et al. [2004]). For photon treatments, the energy is given in megavolts
(MV). The energy has an effect on the distribution of dose inside the patient. Higher
energy radiation penetrates deeper into the tissue. The most common energies for
photons are from 6MV to 18MV.
For the purpose of treatment planning the beam is usually divided into a grid of
beamlets. By moving the leaves during treatment it is possible to modulate the
fluence (radiant exposure) of each beamlet. Beamlets’ fluences make a fluence map
or intensity map for the beam. Modern planning systems include a beams-eye view
(BEV) that projects patient’s 3D image towards the radiation source (Halperin et al.
[2004]). Composing the BEV with the fluence map lets the planner see which areas
will be included in the beam.
6Figure 3 – Varian’s Millennium 80 multileaf collimator can be used to shape the
beam. Image courtesy of Varian Medical Systems, Inc.
2.4 3D Conformal Radiation Therapy
In 3D conformal radiation therapy (3DCRT), the radiation beams are fitted to the
projection of the target (Halperin et al. [2004]). After the 3D image of the patient
has been acquired, suitable beam directions are chosen by the treatment planner
(referred to shortly as planner) using the center of the tumor as the isocenter. Some
beam limiting device can be used to limit the shape of the beam to the projection
of the target, taking into account possible OARs that the planner wants to avoid.
3DCRT planning is an example of a forward-planning method, as it does not require
optimization - the planning system calculates the results of the plan, but it is up to
the planner to tune the parameters. An example BEV from a 3DCRT plan is shown
in Figure 4(a).
2.5 Intensity Modulated Radiotherapy
While the 3DCRT uses uniform fluence for the beams, in intensity modulated radio-
therapy (IMRT) the fluence of each beamlet is assigned separately. The advantage of
IMRT is higher dose conformity, i.e., relatively bigger part of the dose is delivered
to the target instead of healthy tissue, allowing the NTCP to be decreased while
keeping the TCP high. The non-uniform fluence can be realized with the MLC by
moving the leaves during the treatment, thus modulating the time each beamlet is
on. Due to limited speed and precision of the MLC, not all fluence maps can be
realized exactly.
The higher conformity can be seen especially when the target is concave, e.g., a
tumor wrapped around the spinal cord (Grégoire and Mackie [2011]). A downside of
IMRT treatments is that the dose homogeneity for the target may be worse than
in 3DCRT (see for example Arbea et al. [2010]). Also, due to the accuracy of the
beams, the results are more sensitive to patient positioning, patient movement, and
organ movement during treatment.
7(a) A beam’s eye view for a 3DCRT
treatment.
(b) A beam’s eye view showing the flu-
ence map for an IMRT treatment.
Figure 4 – A comparision of 3DCRT (a) and IMRT (b) BEVs. PTV (red structure)
and two OARs (blue and magenta structures) are shown. Using an MLC, the beams
used for 3DCRT treatment can be fitted to the projection of the target volume. However,
also the OAR (magenta) in front of the PTV receives full dose from this beam. A
small margin is used around the PTV to account for imprecision. In IMRT the fluence
maps are optimized to produce a dose distribution with certain properties. The fluence
map is displayd as a colorwash on the BEV, with red being high fluence and blue low
fluence. Higher fluence is assigned to those beamlets that intersect only with the PTV.
In reality this kind of beam angle would probably not be chosen for 3DCRT.
Compared to 3DCRT, IMRT treatments have much more parameters that can be
chosen or optimized. Hence, IMRT treatments are usually created by inverse planning
where the planner defines objectives for the treatment and an optimization algorithm
tries to find parameters that result in the wanted outcome. An example fluence map
of an optimized IMRT plan is shown in Figure 4(b).
2.6 Volumetric Modulated Arc Therapy
In volumetric modulated arc therapy (VMAT), the gantry is rotating while the beam
is on and the MLC’s leaves are moving. Rotation can be either a full 360∘ arc, some
segment of it, or even multiple arcs. The fluences of the beamlets are modulated by
changing the angular velocity of the gantry, changing the intensity of the radiation,
and using the MLC. VMAT can be seen as an extension of IMRT with an infinite
number of fields but homogeneous fluence per angle. In order to increase modulation
per angle, multiple arcs can be used, as the summed up fluence from a given direction
consists of the sum of multiple fluence maps. VMAT allows for better OAR sparing
in some cases, but may also result in larger volume of irradiated tissue (Teoh et al.
[2014]).
8VMAT has the advantage of being faster than IMRT. For example, Quan et al.
[2012] report typical treatment times of 2.6min for VMAT plans with two full arcs,
compared to 4.7–14min for 8–24 beam IMRT plans. The difference in the time
required to deliver the comparable amount of dose is due to the beam being constantly
on in the VMAT treatment as opposed to IMRT where the beam is switched off
while the gantry rotates. Shorter treatment time has multiple advantages. Reducing
the time it takes to treat one patient allows the machine to treat more patients in a
given time, thus reducing the cost of treatment. It is also more comfortable for the
patient and there is less patient movement during the treatment which improves the
accuracy of the dose delivery.
93 Criteria for evaluating treatment plans
The treatment plan creation is a multi-objective optimization problem, with the
high-level objectives being maximal tumor control probability and minimal normal
tissue complication probability. As the objectives are conflicting (higher TCP requires
more radiation which leads to higher NTCP), the treatment planners must decide
on the trade-offs, i.e., which objective is more important and which can be sacrificed
to improve the others. (Halperin et al. [2004])
The high-level objectives such as the TCP and the NTCP depend on the biological
properties of the tumor and normal tissues. Hence, the calculation of the TCP
and the NTCP requires knowledge of biological parameters which are difficult to
determine exactly for each patient. Studies have been done to approximate the
parameters (for example Emami et al. [1991] and Marks et al. [2010]), but the results
so far are inconclusive.
While the use of the TCP and NTCP models in treatment planning is being studied
(Bentzen et al. [2010]), it is not yet a standard practice. In order to compare plans,
metrics that reduce plans into plain numbers are needed. For that purpose the
International Commission on Radiation Units and Measurements (ICRU) develops
recommendations related to radiotherapy, including quantities that can be calculated
from 3D dose distributions and reported.
An important concept relating to the metrics is the prescribed dose. The dose
prescription tells how much radiation is needed for the treatment to be effective
(ICRU [1993]). The prescription can be for example the minimum or mean dose to
be absorbed by the PTV. Using the prescribed dose as the norm, other doses can be
represented relative to it.
This Section presents methods for visualizing the dose distribution and some com-
monly agreed criteria that are then used to analyze the results in sections 5 and
6.
3.1 Isodoses and color washes
The treatment planning system calculates the dose on a 3D image of the patient.
One way to visualize the dose on a 2D view is to show only a single 2D slice of the
3D image. A color wash is formed by coloring the slice based on the dose in each
voxel of the slice.
An isodose is a line made of points with equal dose (Halperin et al. [2004]). For
example the isodose lines for dose levels 90%, 95%, 100%, 105% and 110% (100%
being the prescribed dose) can be drawn to visualize how the dose behaves around
the target and if there are any high-dose regions outside the target.
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3.2 Dose-volume histogram, dose at volume, and volume at dose
Dose-volume histogram (DVH) is a method to visualize how much dose a given
structure receives. The DVH is a 2D graph with volume on the 𝑦-axis and dose on
the 𝑥-axis. The volume is usually shown relative to each structure’s volume; dose
can be either absolute or relative to the prescribed dose.
A DVH can be drawn as cumulative or differential. A differential DVH shows for
each dose the volume that gets exactly that dose, while a cumulative DVH shows for
each dose the volume that gets at least that amount of dose (Grégoire and Mackie
[2011]). In this work DVH refers to the cumulative DVH. Examples of cumulative
and differential DVHs are shown in Figure 5.
(a) (b)
Figure 5 – Examples of cumulative (a) and differential (b) DVHs. The red line is the
PTV and the three other lines (pink, purple and green) are organs at risk.
The DVH graph can be used to analyze both the dose for the target and the doses
for the organs at risk. For the PTV, the planner usually aims for a homogeneous
dose of 100%, which in a DVH corresponds to a line going from (0, 100) to (100, 100)
and then dropping to (100, 0). For OARs, the aim is to have the curves decreasing as
rapidly as possible. When comparing two DVH curves for an OAR, if one is always
below the other, then it is absolutely better. On the other hand, if the two curves
intersect, it is not trivial to know which one should be preferred, as it depends on
how the organ in question responds to radiation. Examples of DVH comparisions
are shown in Figure 6.
The DVH works well for evaluating a single plan, as it gives a good overview of the
doses to different structures. Nevertheless, it is devoid of any spatial information.
For example, it might make a difference if a high-dose region is deep inside the tumor
or close to the border between the tumor and a healthy tissue. In the future there
might be a change from a homogeneous PTV dose to a heterogeneous dose based
on spatial and biological information about the tumor (Bentzen [2005]), in which
case the DVH curve no longer possesses the necessary information to determine the
quality of the PTV coverage.
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(a) Intersecting DVHs (b) DVHs with trade-off
Figure 6 – Examples of DVH comparison between two plans. In (a) the curves for
two plans are intersecting, and so it is not possible to say which one would lead to a
clinically better result without extra information. In (b) the curves show a tradeoff:
the organ drawn in purple receives strictly less dose in plan A (marked with squares)
compared to the plan B (marked with triangles), while for the organ drawn in pink
the plan B is strictly better than plan A.
Comparing different plans by their DVHs becomes complicated if the plans contain
different trade-offs. In such cases the treatment planner typically decides which parts
of the DVH are most important for the TCP and NTCP. Automatic comparison of
DVHs is difficult for the aforementioned reasons. Moreover, when the number of
plans or important structures increases, visual comparison between plans becomes
increasingly difficult.
Instead of analyzing at the DVH graph itself, some specific dose-volume values
can be calculated. Dose at volume, the minimum absorbed dose that covers the
specified volume, is usually written as 𝐷𝑣𝑜𝑙𝑢𝑚𝑒% = 𝑑𝑜𝑠𝑒. Some meaningful values for
targets and organs are 𝐷0%, 𝐷2%, 𝐷50%, 𝐷98%, 𝐷100% and 𝐷𝑚𝑒𝑎𝑛. 𝐷0% and 𝐷100%
represent maximum and minimum doses, respectively, while 𝐷2% and 𝐷98% are called
near-maximum and near-minimum.
Volume at dose, usually written as 𝑉𝑑𝑜𝑠𝑒 = 𝑣𝑜𝑙𝑢𝑚𝑒, represents the volume that absorbs
at least the specified dose. The mean dose to a structure is defined as
𝐷𝑚𝑒𝑎𝑛 =
1
𝑉
∫︁ 𝐷𝑚𝑎𝑥
0
𝐷
𝑑𝑉𝐷
𝑑𝐷
𝑑𝐷, (1)
where 𝑑𝑉𝐷
𝑑𝐷
is the differential volume at dose 𝐷, i.e., the volume that receives exactly
the specified dose.
3.3 Equivalent uniform dose
According to Withers et al. [1988] organs at risk can be classified as serial or parallel,
where serial organs show a threshold response to radiation, while for parallel organs
the response is more graded. Examples of serial organs are the spinal cord and the
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esophagus. Lung and liver are examples of parallel organs. For a serial organ a dose
exceeding a threshold value even in a small volume prevents it from working at all.
While radiation can harm a parallel organ, it will not lose all its functionality even if
parts of its volume receive a high dose.
Equivalent uniform dose (Niemierko [1997]) and its generalization generalized equiva-
lent uniform dose (Niemierko [1999]) attempt to represent the actual dose an organ
receives by a dose that, when distributed uniformly to the whole organ, gives the same
complication probability. For each organ EUD requires a tissue-specific parameter 𝑎,
with 𝑎 = 1 giving serial-like results and higher values (for example 𝑎 = 100) being
suitable for parallel-like organs. Using 𝑎 < 1 (for example 𝑎 = −100), the formula
can also be applied to the target. The problem with EUD is that the results are
strongly dependent on the parameter 𝑎 and it is challenging to determine the exact
value of 𝑎 for each organ. The EUD values are not used in this work.
3.4 ICRU Recommendations
The ICRU report 83 (ICRU83) by Grégoire and Mackie [2011] recommends that
for target structures the values 𝐷2% and 𝐷98% to be reported. Near-maximum and
near-minimum are suggested instead of absolute maximum and minimum since the
real extremes can be highly sensitive to dose calculation resolution and the accuracy
of the structure model and delineation. ICRU83 also recommends reporting the 𝐷50%
or a similar value, and 𝐷𝑚𝑒𝑎𝑛 when deemed clinically relevant - normally for PTV
the 𝐷50% (= 𝐷𝑚𝑒𝑑𝑖𝑎𝑛) is quite close to the 𝐷𝑚𝑒𝑎𝑛.
In addition to the dose levels, the homogeneity of the dose inside the target is often
of interest. For this purpose the ICRU83 suggests the homogeneity index :
𝐻𝐼 = 𝐷2% −𝐷98%
𝐷50%
. (2)
A lower value of HI is preferred, with zero indicating almost perfectly homogeneous
dose for the PTV. It is worth noting that the HI information is included in the dose
values recommended to be reported. The homogeneity index is only valid when the
planner aims for a homogeneous PTV dose.
For critical organs, the relevant dose values depend on whether the organ is serial or
parallel. For serial organs the maximum dose (𝐷2% value) matters the most, while
for parallel organs the mean absorbed dose 𝐷𝑚𝑒𝑎𝑛 is more relevant. For parallel
organs also the volume at a clinically relevant dose can be shown, preferably selected
such that going over that dose has high probability of causing serious complications.
As no organ is completely serial or parallel, ICRU83 recommends reporting all three
values for all organs.
The values calculated for an organ depend on how the organ’s volume is delineated.
For the purpose of this work, the delineation is not a problem as the comparisons are
only between different plans for the same patient with fixed structures. Note that
13
the organs usually receive a highly inhomogeneous dose, and hence the median dose
might differ greatly from the mean dose. The clinically relevant doses for different
organs have been studied for example in Emami et al. [1991] and updated in Emami
[2013].
Hot spots are defined to be the volumes outside the PTV that receive a dose larger
than 100% of the specified PTV dose. (ICRU [1993]). A hot spot with diameter less
than 15mm is in general not considered relevant, unless it is inside a small organ,
such as eye or optic nerve. In this thesis only the total volume of the hot spots is
calculated and reported as hot spots outside target (HOT).
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4 Overview of optimization
Traditionally the treatment planning has been a forward planning process, where the
planner chooses the values for possible parameters (e.g., number of beams and beam
directions), calculates the dose, evaluates the plan, and modifies the parameters if
necessary. Designing IMRT or VMAT treatments manually is not feasible due to the
large number of parameters (e.g., the MLC positions at each time step). For this
reason, the modern treatment planning systems are based on inverse planning concept:
the planner describes the wanted outcome and the planning system calculates the
parameters to achieve it.
In IMRT, each beam is discretized into a grid of beamlets of fixed size that is usually
specified on the isocenter plane. The fluence (intensity) of each beamlet can be set
almost independently of other beamlets, giving rise to the term intensity modulation.
After the fluences for a beam are determined, the corresponding MLC positions can
be calculated. Due to the physical limitations of the MLCs, not all fluences are
achievable.
According to Bortfeld et al. [1992], dose can be described as
𝑑 = 𝐷𝑥, (3)
where 𝑥𝑘 is the fluence of beamlet 𝑘, 𝑑𝑖 is the resulting dose in voxel 𝑖, and 𝐷 is the
dose calculation matrix, with 𝐷𝑖𝑘 containing the contribution of beamlet 𝑘 to voxel
𝑖. Solving the inverse planning problem would mean inverting the matrix 𝐷 and
calculating 𝑥 = 𝐷−1𝑑. However, the matrix is generally not invertible and even if
it was, the result could include negative intensities which is clearly not physically
plausible. For that end, planning systems include algorithms that can be used to
optimize the plan with regards to given objectives. This results in a multi-objective
optimization problem and the objectives need to be converted into a single objective
function. Typically the user can specify priorities or weights for each objective, and
the optimizer sums their weighted costs to produce a single cost value.
The optimization algorithms are typically iterative, improving the solution on every
iteration through for example a gradient descent. Other optimization methods are
discussed shortly in Section 4.4. The rest of this section is specific to the Eclipse
Treatment Planning System and its Photon Optimizer algorithm (Varian Medical
Systems, Inc [2015a]) which are used in this work.
4.1 Dose calculation
An important part of the optimization is dose calculation. The treatment plan
is usually represented as fluence maps for each beam direction, but all currently
used objectives operate on the dose distribution. The dose calculation needs to
convert optimized fluences to realistic leaf motion sequences and then to actual doses.
In Eclipse, the actual dose is usually calculated using the Anisotropic Analytical
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Algorithm (AAA) based on Ulmer and Harder [1995] and developed further in
Tillikainen et al. [2008]. The AAA is a Monte Carlo based convolution superposition
algorithm, i.e., it uses separate kernels for different kinds of radiation (primary
photons, scattered extra-focal photons, scattered electrons) to convolute beamlets
and then sums the results to get the final dose.
The whole process of realistic and exact dose calculation is quite slow, and the
optimizers usually use a less accurate but faster dose calculation engine. The
lightweight dose calculation algorithm used in Eclipse is the Multi-Resolution Dose
Calculation (MRDC) algorithm (Varian Medical Systems, Inc [2015a]).
To reduce the difference between the optimizer dose and the final dose, an intermediate
dose calculation can be performed to calculate a correction term. The correction
term is calculated by subtracting the optimizer dose matrix from the more accurate
intermediate dose. The term is then added to the doses from subsequent iterations
to correct some of the difference. Using the intermediate dose helps in two ways: it
gives the user a more realistic idea of the final dose, and it can make the objectives
more meaningful. This is especially important when trying to replicate existing dose
distributions. Eclipse allows running the intermediate dose calculation directly during
the optimizer, in which case it is based only on the optimized fluences instead of real
leaf motions. Other option is to perform accurate leaf motion and dose calculations
after optimization and then continue the optimization using the calculated dose as
the intermediate dose.
4.2 Objectives
There are three types of objectives: upper, lower and exact. An upper objective
means that the specified value should not be exceeded, and is usually used for organs
at risk and to restrict the maximum dose inside the target. A lower objective specifies
a value that should be achieved. Lower objectives are used to make sure that the
target receives a sufficient dose. An exact objective should be matched exactly, and
it is used in some cases for targets. Using lower or exact objectives for OARs is in
general not suggested as it conflicts with the clinical objective of minimizing the dose
to healthy tissues.
The optimization objectives must be differentiated from the clinical goals. While
clinical goals aim to specify the outcome of the treatment, optimization objectives
are more technical and used to direct the optimizer. However, some clinical goals
may be directly convertible to optimization objectives. With the development of
more biologically and clinically relevant plan metrics such as the EUD, the TCP,
and the NTCP, the role of the clinical goals in the optimization may increase.
Eclipse requires the user to set a priority for each objective. Internally the priorities
are converted into weights using a superlinear formula. The weights are then used
when the costs and gradients are summed together.
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4.2.1 Dose-volume objective
A dose-volume (or DVH) point objective is the most basic type of objective. An
upper (lower, exact) point objective indicates that the dose at some volume should
not be more (be less, differ) than what is specified in the objective. Using the DVH,
the cost of an upper dose-volume point objective is calculated as
𝑐(𝑑, 𝑣) =
∫︁ 𝑉𝑑
𝑥=𝑣
1
2(𝐷𝑥 − 𝑑)
2 d𝑥, (4)
where 𝑑 is the objective dose level, 𝑣 is the objective volume level, 𝐷𝑥 is the actual
dose at volume 𝑥 and 𝑉𝑥 is the actual volume at dose 𝑥. The formulas for lower and
exact objectives are analogous.
In practice the cost is calculated inside the structure for which the objective is
specified. For each voxel where the dose is higher (lower) than the specified dose and
lower (higher) than 𝐷𝑣, the cost is calculated and added to the total cost of that
objective. For the same points, gradients of the cost functions are also calculated
and added to the gradient matrix. For a voxel 𝑖, the cost and the gradient of an
upper point objective are given by
𝑐𝑖(𝑑, 𝑣) =
⎧⎨⎩
1
2(𝐷𝑣 −𝐷𝑖)2, if 𝐷𝑣 > 𝐷𝑖 > 𝑑
0, otherwise
(5)
and
𝑐′𝑖(𝑑, 𝑣) =
⎧⎨⎩𝐷𝑣 −𝐷𝑖, if 𝐷𝑣 > 𝐷𝑖 > 𝑑0, otherwise (6)
respectively, with 𝐷𝑖 being the dose at voxel 𝑖. The costs and gradients of lower and
exact point objectives are similar.
A line objective can be used to replace a continuous group of point objectives
associated with the same structure. The advantages of a line objective compared to
using many point objectives are that it is faster to calculate and thats it does not
create unnecessary local optima. The cost and the gradient of a line objective are
analogous to the point objective.
4.2.2 Normal Tissue objective
The normal tissue objective (NTO) works as a general tool to limit the radiation
outside of the target. Its main use is to prevent hot spots, but it can also be used
to obtain sharp dose gradients around the target. Eclipse supports manual and
automatic NTOs. For a manual NTO, the user has to specify four parameters:
margin 𝑥𝑠𝑡𝑎𝑟𝑡, start dose 𝑓0, end dose, 𝑓∞ and falloff 𝑘. The upper limit for dose at
distance 𝑥 from the border of the target can then be calculated as
𝑓(𝑥) =
⎧⎨⎩𝑓0𝑒−𝑘(𝑥−𝑥𝑠𝑡𝑎𝑟𝑡) + 𝑓∞(1− 𝑒−𝑘(𝑥−𝑥𝑠𝑡𝑎𝑟𝑡)), 𝑥 ≥ 𝑥𝑠𝑡𝑎𝑟𝑡𝑓0, 𝑥 < 𝑥𝑠𝑡𝑎𝑟𝑡. (7)
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In case of multiple targets, NTO is calculated for each voxel with regards to the
target that yields the highest value. When using the automatic NTO, the software
determines the parameters dynamically during optimization with the aim of reducing
dose in high dose regions outside the target.
4.2.3 gEUD objectives
The optimizer also supports lower, upper and exact objectives specified through the
generalised Equivalent Uniform Dose. Using gEUD in optimization requires the user
to specify the biological parameter 𝑎 used for calculating the gEUD value. The cost
arising from an gEUD objective is based on the quadratic difference between the
target value and the structure’s current gEUD value. The gEUD objectives are not
used in this work.
4.3 IMRT optimization
IMRT treatments can be planned using an iterative gradient search optimizer (Varian
Medical Systems, Inc [2015a]). The workflow that is iterated is the following:
1. Calculate dose based on fluence maps.
2. Calculate objective costs and gradients based on dose.
3. Project gradients to fluence maps.
4. Optimize fluence map gradient weights using line search.
5. Modify fluence maps accordingly.
During each iteration, the algorithm updates the dose matrix and the gradient matrix.
The dose is calculated separately for each field. Field doses are mapped to the dose
matrix and summed. Objective costs and gradients are calculated for each voxel
related to the objective as specified in Section 4.2. The gradient is projected to the
fields’ fluence maps and a line search is conducted to find the minimum cost.
After each iteration, the optimizer evaluates a convergence criteria. The criteria can
be for example the relative improvement of total cost during the last iteration. If
the improvement is smaller than a predefined value, the algorithm is said to have
converged.
The optimizer tries to find the optimal fluences for each beam. It does not take into
account the physical constraints of the multileaf collimator. The optimizer smooths
the fluence maps on each iteration in order to prevent too sharp gradients, thus
reducing the difference between the optimal and the actual fluences.
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4.4 Other optimization methods
As Langer et al. [2003] note, optimization algorithms can be divided into three
categories: those that find some local optima, those that find a local optima with
bounds on the error, and those that always find the global optima.
According to Deasy [1997], using dose-volume constraints or optimizing beam angles
may lead to the problem having multiple local minima. If only minimum or maximum
dose objectives or quadratic deviation from a prescribed dose are used as the cost
function, then only a single minimum exists and the gradient search will converge
to the global optimum (Webb [1994]). Wu and Mohan [2002] did not find clinically
relevant differences between the local and global optima when using dose-volume
constraints.
Also other optimization methods are possible. Lee et al. [2003] formulated the IMRT
inverse problem, including beam angle optimization, as a mixed integer program that
can be solved to get a provenly optimal result. In a clinical case they assume to have
tens of thousands of constraints and variables, which enforces them to introduce
specialized heuristics to make the problem tractable. The heuristic method allows
them to produce a feasible solution quite fast, while reaching the provenly optimal
solution takes much (20− 50 times) longer. Still, being able to reach the optimal
solution allows to analyze how close the first feasible solution is to the globally
optimal solution. In their test cases the difference in objective values ranges from
13.5% to 33%, but it is not analyzed if the difference between the feasible and
optimal solutions is clinically relevant. No comparison between the MIP and other
methods is presented.
Metaheuristic approaches, such as simulated annealing and genetic algorithm, can
also be used (Halperin et al. [2004]). These methods explore the solution space in
a partly stochastic way, being so able to examine multiple different solutions. The
best solution is then chosen, but the methods cannot guarantee that it would be the
global optima. The metaheuristics are also much slower than deterministic heuristics
such as gradient methods, which discourages their usage.
For VMAT treatments, a different optimization method is required due to the
theoretically unlimited number of beam directions and the restrictions for the change
in fluencies between consecutive angles. VMAT optimization is not discussed in this
work, for more information see for example Otto [2008] and Varian Medical Systems,
Inc [2015a].
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5 Spatial objectives in treatment planning
A spatial objective is a 3D matrix where each voxel, mapping to a point in the
patient’s body, is assigned a dose value. Depending on the type of the objective
(upper, lower, or exact), the dose in the corresponding body location should not
exceed, be lower than, or differ from the specified value.
Currently none of the major treatment planning systems support spatial objectives
as such. The only way to pass spatial information to the optimizer is by creating
optimization structures (structures with no biological meaning), and assign them
dose-volume objectives. For example, the planner may create a structure for a hot
spot volume to reduce its dose. More detailed control, such as specifying a gradient, is
not feasible using the dose-volume objectives only. In this thesis the spatial objectives
are analyzed in the context of Eclipse’s Photon Optimizer algorithm.
The idea of a spatial objective is not new. For example Webb [1994] uses a cost
function based on the quadratic difference between a prescribed dose and the current
dose. Eclipse’s normal tissue objective is effectively a spatial objective. The difference
is in how the spatial objective dose is defined. Webb only uses a single dose level
for the target, another dose level for the OARs, and a third dose level for the rest
of body. Normal tissue objective’s values are calculated based on the distance to
targets. The spatial objective presented here allows the user to set the target levels
individually for each voxel.
For the purpose of this work Eclipse was modified to support the spatial objectives
through the Eclipse Scripting API (ESAPI). Currently, the API allows the user to
query the size, the resolution, and the position of the spatial objective matrix. The
user can also set the dose values of the objective matrices, as well as the weights of
the objectives. The dose value can also be set to undefined in which case the voxel
is skipped when calculating the cost and the gradient of the objective. Only upper
and lower spatial objectives are supported, but they can be combined to form an
exact spatial objective. The spatial objectives can be used in combination with other
objectives.
In this section the aim is to evaluate the spatial objective rather than the accuracy of
the optimizer’s dose calculation. Hence, the tests in this section are done using the
doses calculated by the optimizer. The effect of the differences in dose calculation is
discussed in Section 6.
5.1 Spatial objective definition
During each iteration, the optimizer calculates the cost and the gradient of the spatial
objectives by looping through each voxel in the dose matrix and comparing the voxels’
dose values to the corresponding values in the objective matrix.
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The cost 𝑐𝑖 and the gradient 𝑐′𝑖 of the upper spatial objective for voxel 𝑖 are calculated
as follows:
𝑐𝑖(𝑑) =
⎧⎨⎩
1
2(𝐷𝑖 − 𝑑𝑖)2, if 𝐷𝑖 > 𝑑𝑖
0, otherwise
(8)
𝑐′𝑖(𝑑) =
⎧⎨⎩𝐷𝑖 − 𝑑𝑖, if 𝐷𝑖 > 𝑑𝑖0, otherwise (9)
were 𝐷𝑖 is the current dose at voxel 𝑖 located at (𝑥𝑖, 𝑦𝑖, 𝑧𝑖) and 𝑑𝑖 is the objective
dose at the same voxel. The formulas for the costs and gradients of the lower spatial
objective are similar:
𝑐𝑖(𝑑) =
⎧⎨⎩
1
2(𝐷𝑖 − 𝑑𝑖)2, if 𝑑𝑖 > 𝐷𝑖
0, otherwise
(10)
𝑐′𝑖(𝑑) =
⎧⎨⎩𝐷𝑖 − 𝑑𝑖, if 𝑑𝑖 > 𝐷𝑖0, otherwise, (11)
and an exact spatial objective can be created by combining lower and upper spatial
objectives with same objective dose:
𝑐𝑖(𝑑) =
1
2(𝐷𝑖 − 𝑑𝑖)
2 (12)
𝑐′𝑖(𝑑) = 𝐷𝑖 − 𝑑𝑖. (13)
The total cost of the spatial objective is given by summing the costs of all voxels
for which the objective has been set. The gradients are added to the corresponding
elements in the optimizer’s gradient matrix.
Quadratic cost [Eqs. (8, (10) and (12)] was chosen due to it being used already in
the normal tissue constraint as well as the other constraints. The gradient of the
quadratic cost is linearly relative to the difference between the targeted and achieved
doses [Eqs. (9), (11) and (13)]. A constant gradient resulting from linear cost would
not prioritize the voxels based on the dose difference at all, and a superlinear gradient
would probably give too much weight to single voxels with large differences.
5.2 Testing with a simple plausible dose on a model patient
The first test is to check if the spatial objectives can direct the optimizer to reproduce
a simple but physically plausible dose distribution. Instead of using a real patient
data, a cube of uniform tissue was created, with a spherical target structure in its
center. This kind of artificial patient is called a phantom.
The spherical PTV was given a homogeneous dose through optimization with dose-
volume objectives (visualized in Figure 7). The resulting dose was set as the lower
and the upper objectives, creating in effect an exact objective.
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(a) A 2D colorwash visualiza-
tion of the dose in the center
slice.
(b) A 3D visualization of the
phantom and the dose.
Figure 7 – Figures (a) and (b) visualize the reference dose. The dose is highest in the
intersection of the beams (red) and lowest in parts outside of all beams (darker blue).
In Figure (a), one of the beams is also drawn for reference. The target is indicated by
the red circle.
In the optimizer algorithm the spatial dose objective matrices must coincide with
the optimizer dose matrix so that the cost can be calculated for each voxel. If the
resolution or position of the spatial objective matrices do not match with those of the
optimizer’s dose matrix, the optimizer has to convert the matrix to its internal format
by approximating the objective values at missing voxels, using for example trilinear
interpolation. As the dose distribution does not change linearly, the interpolated
values might differ from the calculated values. If the approximated value is higher
than the actual value in a lower objective (or respectively lower in an upper objective),
the optimizer will try to increase (decrease) the value at that voxel, but as increasing
the dose at one voxel necessarily affects also the neighboring voxels, this causes the
optimizer to deviate from the original objective dose.
The first phantom used here had a 5mm interval between the slices in the dose
matrix, while the optimizer uses 2.5mm slicing, so the optimizer had to interpolate
the values for every second slice. In Figure 8(a) it can be seen that in even slices
error is negligible, while the odd slices (interpolated) do show differences between the
calculated and the interpolated doses. The differences are especially strong in the
slices where the dose changes are large and non-linear, for example at the borders of
the beams [Figure 8(b)].
Other possibilities for treating missing values would include using one of the neigh-
boring voxels’ value or skipping the missing values entirely. To mitigate the problem
outlined above, minimum (maximum) neighbor value from the objective matrix
should be used for lower (upper) objective. Skipping non-coinciding voxels could be
problematic if the number of such voxels is large, as it results in loss of information.
In the worst case, no voxels coincide, leading to the spatial objective being discarded
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Figure 8 – The difference between interpolated and calculated doses. Panel (a) shows
that there are significant differences only on the interpolated (odd) slices. Panel (b)
shows the differences on slice 41, on the lower end of the beams, where the differences
between interpolated dose and calculated dose are relatively large. The values shown
are relative to the prescribed dose.
totally. When possible, the best option is to make sure that the optimizer dose
matrix and Eclipse’s objective matrices coincide, in which case there are no missing
values. This approach is used for the tests in this thesis.
In this case the problem was fixed by creating another phantom with 2.5mm slic-
ing interval. A similar dose distribution was created using the same dose-volume
objectives, and the resulting dose was set as the spatial objectives.
Using only upper and lower objectives with a dose that is known to be achievable
means that at least one zero-cost global minimum must exist in principle. In practice
factors such as the fluence smoothing and the fact that the optimizer is an iterative
algorithm may prevent the optimizer from reaching the zero-cost minimum. In this
case, the optimizer detects convergence after 70 iterations with costs 12.246 and
12.073 for upper and lower spatial objectives, respectively. The reported costs depend
on the spatial objective weights and the objective costs and only their relative scale
is relevant. These costs are small compared to the initial cost (about 264000 for
lower spatial objective), but still significantly larger than zero.
The optimizer’s convergence criteria is triggered if the improvement per iteration
is very small. The criteria is a heuristic meaning that significant improvements
after the convergence are unlikely, but not impossible. In order to see if the small
improvements would sum up to a significant improvement over time, the same plan
was optimized up to 1000 iterations.
The logarithm of the total cost after each iteration is shown in Figure 9. Initially
the cost decreases very fast. Around iteration 70 the improvements are very small
and convergence is detected. Very slow progress continues until around iteration
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Figure 9 – The total cost of the objective function as a function of the iteration. Note
the logarithmic 𝑦-axis.
350, where the cost begins to decrease again. This suggests that the algorithm gets
stuck in a local optimum or in a zig-zag-motion. After calculating the gradient the
optimizer performs a line search in order to find the local minimum. The range for
the line search is modified internally at each iteration, and the escapes seemed to be
correlated with increased range.
The total cost after 1000 iterations is around 1 and still decreasing on each iteration.
These results show that while the optimizer is able to get very close to the exact dose
specified by the spatial objectives, it may get stuck in a local optimum or in a zig-zag
motion. This suggests that the optimizer algorithm could be improved. For example,
allowing the optimizer to occasionally choose a move that increases the cost might
allow it to escape the local minima faster. However, improving the optimizer in this
respect is outside of the scope of this Thesis. Since the initial result is already very
close to the targeted dose, it is unlikely that the local optima would have much effect
in the plan conversion case where a zero-cost global optimum does does not exists.
These tests were performed using the fluence smoothing. Turning it off seemed to
worsen the results. It might be that smoothing the fluence maps smooths also the
optimization landscape and allows the gradient descent to find a better solution.
5.3 Testing spatial objectives with realistic treatment plans
5.3.1 Test setup
To test the spatial objectives’ capability to guide the optimizer in recreating a realistic
dose distribution and to see how different parameters affect the result, two IMRT
plans were generated, one for a prostate patient (A) and one for a head and neck
patient (B). These are two cancer types commonly treated with external radiation.
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Upper and lower point objectives were added for the PTV(s) in both plans. For
OARs, upper point and line objectives were added. The manual NTO was also
used. The objectives were created using Eclipse’s RapidPlan tool (see Varian Medical
Systems, Inc [2015b]) and they can be assumed to be clinically realistic. The plans
were optimized until the optimizer algorithm converged according to its default
convergence criteria. These two plans (denoted A0 and B0 hereafter) were then used
as the reference for the following experiments.
Four variations were created from both base plans. First replaces the original
objectives with DVH line objectives (upper for OARs, exact for targets) created from
the DVH curves of the reference plans A0 and B0. For PTV(s), also lower and upper
point objectives were used, based on doses at 2% and 98% volumes. The objectives
were set to 0% and 100% volumes respectively. The stretching was done in order to
convey the original wish better to the optimizer. The resulting plans (denoted A1
and B1), are used as a baseline against which the spatial objectives are compared.
Using the dose-volume objectives is one possible heuristic for plan conversion. For
example the plan conversion method currently used in Eclipse is based on DVHs.
Here it also allows to compare the differences in the resulting dose as well as the
time the optimization takes.
In the second variation the original objectives were replaced with lower and upper
spatial objectives. Both spatial objectives used the dose of the reference plans (A0
or B0), and they had equal priorities, creating in effect an exact objective that aims
to reach the reference dose. These plans are denoted by A2 and B2.
The third set of plans (denoted A3 and B3) is a variation of the second, such that the
lower spatial objective is only set for a control structure (denoted PTV+10mm), the
volume of which consists of the the target structure(s) extended with a 10mm margin.
In theory having a lower objective for the whole body should not worsen the results
if the optimizer is able to reach the wanted dose exactly. However, by definition the
PTV includes all the volume containing tumor, and hence there is no clinical reason
to have a lower limit on the dose outside of the PTV. Especially if the optimizer’s
dose matrix does not match the spatial objective matrix and interpolation is needed,
the interpolated lower objective values might cause the optimizer to increase the dose
to other body parts compared to the original plan. Plans A3 and B3 are compared
to A2 and B2 to analyze these effects. The margin size of 10mm was chosen based
on informal tests where it seemed to produce best results. For these test cases the
optimizer dose matrix has a resolution of 1.875mm and a 10mm margin is therefore
equivalent to approximately five voxels. The optimal size of the margin is studied in
more detail in Section 5.3.5.
The fourth set of plans is a combination of variations 1 and 2: exact spatial objectives
and dose-volume objectives generated from the reference plan’s DVHs. The priorities
of the spatial objectives were set such that their costs are of the same magnitude as
the sum of costs of the DVH objectives. These plans are denoted by A4 and B4.
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The plans were then optimized for different number of iterations. The used iteration
counts were “auto”, 50, 100, 200, and 1000 for case A and “auto”, 20, 35, 50, and
1000 for case B. Here “auto” indicates that the optimization was stopped once
it detected convergence. The 1000 iterations versions were done in order to see if
the local optimum effect also occurs in the cases with realistic dose distributions.
Otherwise only the iteration counts close to the “auto” convergence are considered,
as optimizing for 1000 iterations is not feasible in practice. The iteration count is
shown as a suffix, e.g., A1-50.
5.3.2 The metrics used to analyze results
The comparisons here are based on the speed (time per iteration and number of
iterations required) and on how close the result is to the reference plan’s dose. The
accuracy is measured using the root mean square error
RMSE(𝑆) =
⎯⎸⎸⎷ 1|𝑆|∑︁𝑖∈𝑆(𝑥𝑖 − 𝑥𝑜𝑖 )2, (14)
where 𝑥𝑜𝑖 is the dose value at voxel 𝑖 in the reference dose, 𝑥𝑖 is the dose value at
voxel 𝑖 in the dose for which the RMSE is calculated, 𝑆 is the set of voxels for
which the RMSE is calculated, and |𝑆| is the number of voxels in the set. The dose
values are relative to the prescribed dose, so the unit of the RMSE is percentage
points, abbreviated as 𝑝𝑝. For each variation the RMSE is calculated for all relevant
structures, including the body structure which contains the whole dose matrix.
It is worth noting that the RMSE is not related to the clinical quality of a plan.
For example, a plan having lower dose to an OAR when compared to the reference
plan leads to that structure having a large RMSE, even if the lower dose would be
clinically favorable. However, the aim of this section is to evaluate if the spatial
objectives can be used to produce a given dose distribution, and for that purpose
the RMSE is relevant. The clinical aspect is taken into consideration in the plan
conversion case studied in Section 6.
5.3.3 Results
The results in Table 1 show that the spatial objectives are capable of directing the
optimizer very close to a desired dose distribution at least when it is physically
feasible.
On all test cases, the versions utilizing spatial objectives reach a better (in terms
of lower RMSE for body) result than the one based on only DVH curves. For the
PTV+10mm structures no DVH objectives were generated, as those are not clinical
structures but only used for control purposes, e.g., to set the spatial objectives and
to calculate the RMSE. In the case with only DVH-objectives (A1) the control
structure has the highest RMSE of all structures, while using spatial objectives it
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Table 1 – The RMSEs for the body structure (i.e., the whole dose matrix) for different
iteration counts. Variation 1 has the highest RMSE of the four cases, while the versions
that use spatial objectives have significantly lower RMSE.
1 [𝑝𝑝] 2 [𝑝𝑝] 3 [𝑝𝑝] 4 [𝑝𝑝]
A-50 1.446 0.215 0.212 0.183
A-100 1.423 0.197 0.178 0.145
A-200 1.423 0.191 0.172 0.105
B-20 4.692 0.426 0.569 0.410
B-35 4.591 0.380 0.481 0.345
B-50 4.563 0.371 0.458 0.342
has RMSE comparable to other structures (c.f. Table 2). This suggests that it is
important to specify objectives for all relevant structures when using the DVHs as
means of replicating a dose.
Table 2 – The RMSEs for the different structures and variations for case A.
Plan Body [𝑝𝑝] PTV [𝑝𝑝] PTV+10mm [𝑝𝑝] Bladder [𝑝𝑝] Rectum [𝑝𝑝]
A1-200 1.423 0.572 2.758 1.96 2.005
A2-200 0.191 0.654 0.569 0.368 0.481
A3-200 0.172 0.575 0.507 0.330 0.479
A4-200 0.105 0.274 0.293 0.214 0.210
For the PTV, the DVH objective results in a lower RMSE than the spatial objectives.
This is probably due to the PTV point objectives being tightened so that they ended
up being quite close to the original PTV objectives. This in addition to the PTV
objectives having the highest weights may lead the optimizer to produce similar dose
for the targets. Also the difference in the objective weights explains why the OARs
show larger error than the PTV for variation 1.
The difference in the results when setting the lower spatial objectives to the whole
body or only for the target is small (variations 2 and 3). Analyzing the target
DVHs in the two variations (Figure 10), both versions seem to have similar behavior
(smoother corners meaning less homogeneous dose), but for the variation 3 the mean
dose is much closer to the reference plan, resulting in slightly smaller RMSE.
The results after 1000 iterations are shown in Table 3. When using only dose-volume
objectives, there is very little or no improvement in the body RMSE. When spatial
objectives are used, the improvement is significant. An exception is the B3-variation,
where the additional iterations do improve the result slightly, but not that much.
The result is due to the optimizer not increasing the line search range sufficiently in
order to find a better solution. These results again suggests that there is room for
improvement in the optimizer when the spatial objectives are used.
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Figure 10 – The DVH curves for the PTV in the reference plan (squares), variation
2 (triangles) and variation 3 (circles). Both variations lead to similar curve, but the
variation 2 has slightly worse mean dose.
Table 3 – The RMSEs for the body structure (i.e., the whole dose matrix) at conver-
gence and after 1000 iterations. For case A also the results after 200 are shown. For
the “auto” case, the number of iterations is shown in brackets.
1 [𝑝𝑝] 2 [𝑝𝑝] 3 [𝑝𝑝] 4 [𝑝𝑝]
A-auto 1.525 (36) 0.200 (82) 0.180 (93) 0.135 (122)
A-200 1.423 0.191 0.172 0.105
A-1000 1.423 0.006 0.000 0.021
B-auto 4.527 (90) 0.373 (44) 0.463 (45) 0.320 (55)
B-1000 4.488 0.028 0.337 0.046
5.3.4 Effect of spatial objectives in iteration time
The speed of optimization depends on two factors: the time spent per iteration and
the number of iterations required. Not much can be said from the required number
of iterations due to the small amount of data used here, but the time spent per
iteration can be analyzed.
Table 4 – Times per iteration for each variation of objectives for cases A and B. The
times were averaged over five runs, and the standard deviations are also shown. The
optimizer is deterministic, so the variation comes from the computer on which the tests
were run. The time reported by the optimizer includes some preprocessing overhead,
leading to systematic difference in time spent per iteration depending on the number
of iterations. Here only the comparison between the variations is of interest.
Variation 0 [𝑚𝑠] 1 [𝑚𝑠] 2 [𝑚𝑠] 3 [𝑚𝑠] 4 [𝑚𝑠]
A100: 513± 10 525± 6 677± 17 637± 14 672± 18
B50: 464± 36 477± 14 535± 11 534± 8 599± 20
For both patients, the original objectives and the copied DVH objectives result in
fastest iterations (Table 4). Using the spatial objectives is slower. Restricting the
lower spatial objective to the target makes the iterations slightly speedier since the
voxels where the objective is not set can be skipped faster.
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Using many DVH objectives makes iterations slower. Each structure that has at
least one volumetric constraint (DVH point or line objective) needs to have its DVH
calculated. In addition, the calculation time of the costs for a structure is relative to
the volume of the structure and the number of dose-volume objectives it has. The
spatial objectives’ cost calculation time is relative to the volume of the objective
matrix. However, most of the time during one iteration is spent in other parts of the
optimizer, so the differences caused by the objectives are fairly small.
The time the optimizer uses per iteration is a sum of many different operations. A
break-down of an average iteration is shown in Table 5. Approximately one third of
the time is spent on calculating the gradient matrix, projecting it to fluence gradients,
and calculating the dose change. The rest is used in the line search phase and to
send and receive data between the optimizer and Eclipse.
Calculating the gradient for the dose matrix is quite fast (order of 10ms), but it
reflects the computational costs of the objectives quite well. Variation 1, that uses
only dose-volume objectives, is faster than the variations 2 and 3 that use spatial
objectives. The variation 4 that combines DVH objectives and spatial objectives is
the slowest. A notable difference is the field gradient calculation phase, which seems
to be much slower when spatial objectives are used. The reason is probably that
when only dose-volume objectives are used, large amount of the voxels in the gradient
matrix are zero and can be skipped. The spatial objectives result in most voxels in
the gradient matrix having a value different from zero. Also the time taken by line
search, input, output, and other functions is significantly higher for the versions that
use spatial objectives. That is caused at least partly due to inefficient handling of
input data (i.e., some properties of the spatial objective matrices are read on each
iteration).
Table 5 – Time consumption of different steps in optimization for an average iteration.
The times are calculated for a representative run from the test summarized in Table 4.
The times are in milliseconds. Also the percentages of total time spent are shown.
A0 [ms] A1 [ms] A2 [ms] A3 [ms] A4 [ms]
Dose gradient 10 (3%) 7 (2%) 15 (3%) 13 (3%) 18 (3%)
Field gradients 64 (17%) 65 (17%) 96 (19%) 82 (17%) 96 (19%)
Doses 55 (15%) 56 (15%) 55 (11%) 54 (11%) 55 (11%)
I/O and others 239 (65%) 250 (66%) 352 (68%) 335 (69%) 340 (67%)
TOTAL 369 378 517 485 509
5.3.5 Choosing an optimal margin
Based on the two test cases in Table 6, it is not clear whether it is beneficial to have
the lower objective for full body. In case A, setting the lower spatial objective only
to the target produces better results for each strucure, including body and PTV. It
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also improves the speed. In case B, the all-body version produces lower RMSE for
body but higher for both targets. Most of the OAR structures have lower RMSEs on
the full-body version, but it can be argued that the PTV dose is the most important.
The differences are nevertheless very small.
Table 6 – The RMSEs for different structures and the two ways of using spatial
objectives for cases A and B. In case A, OARs 1 and 2 are bladder and rectum,
respectively. In case B, the OARs are brainstem and spinal cord, and the PTV marks
the union of both PTVs.
Plan Body [𝑝𝑝] PTV [𝑝𝑝] OAR 1 [𝑝𝑝] OAR 2 [𝑝𝑝]
A2-200 0.191 0.654 0.368 0.481
A3-200 0.172 0.575 0.330 0.479
B2-50 0.371 1.322 0.276 0.371
B3-50 0.458 1.292 0.235 0.533
In order to test there is an optimal margin for the lower spatial objective, the cases
A3 and B3 were optimized with spatial objectives such that the lower objective was
set for different volumes. The volumes used were whole body, PTV, and PTV with
different margins (−10mm, 5mm, 10mm, 20mm, 30mm, and 50mm). The RMSEs
were calculated for the PTVs and OARs. The negative margin produced very bad
results in terms of the RMSE, as one could expect. The optimizer tries to increase
the dose level only in the voxels for which a lower objective has been specified. Thus,
not specifying a lower dose objective for the whole PTV leads to improved OAR
sparing but clinically unacceptable dose coverage for the PTV.
Figure 11 – The RMSEs for case A after 100 iterations of optimization. The lower
objective is set for seven different volumes: PTV, PTV with different margins, and full
body. Different volumes are represented with different colors.
The results for non-negative margins are shown in Figures 11 (case A) and 12 (case B).
All variants with at least some margin produced similar results, while the PTV-only
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Figure 12 – The RMSEs for case B after 50 iterations of optimization. The lower
objective is set for seven different volumes: PTV, PTV with different margins, and full
body. Here PTV means the union of PTV Low and PTV High. Different margins are
represented with different colors.
version produced relatively bad results on almost all structures for both patients. As
an exception, the PTV-only version produced the best result for PTV. The result
may be due to a smaller volume of exact spatial objective being able to produce a
better result inside the volume where it is specified as it leaves the optimizer more
freedom outside the exact objective.
A close-up of the PTV DVHs for case A reference plan, the PTV-only variant, and
the 10mm-margin variant are shown in Figure 13. While the PTV-only variant
results in a DVH that is closer to the reference plan’s DVH for the dose fall-off, the
10mm-margin case has smaller low-dose volume. Having a less steep slope in the
PTV-only case allows the optimizer to reduce the dose to other parts of the body,
thus leading to a high RMSE for other structures.
Based on the obtained results it seems that setting the lower spatial objective for
the PTV only is not enough. Instead, a margin of at least 5mm should be used
around the target in order to prevent underdosage in the border of the target. The
effect of the size of the margin seems to be insignificant. The lower spatial objective
can also be set to the whole body, at least in these cases where where the targeted
dose distribution is known to be possible. For case A, a 5mm margin seems to be
optimal, while for patient B setting the lower spatial objective to the whole body
results in the smallest body RMSE. It is likely that the optimal margin has to be
determined on case-by-case basis. Nevertheless, the differences are small.
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Figure 13 – The PTV dose volume histogram for the case A reference plan (squares),
for the PTV-only variant (triangles), and for the PTV plus 10mm-margin variant
(circles). The PTV-only variant provides a DVH closer to the reference plan but the
10mm-margin variant has better dose homogeneity. Overall the differences are very
small.
5.3.6 Choosing an optimal priority
In order to test the effect of the (relative) priorities of the objectives plans for cases
A3 and B3 were optimized with different priorities for the lower spatial objective,
while keeping the upper spatial objective priority constant (100). The priorities used
for the lower spatial objective were 50, 75, 90, 100, 110, 125, 150 and 200.
The results for the case A are shown in Figure 14. Although the differences are
not very large, the results indicate that the priority of the lower spatial objective
should be at least as large as the upper spatial objective priority. The best results
are obtained with priorities 125 (PTV) and 200 (Body).
For the case B, the results are similar (see Figure 15). Again the best priority depends
on the structures, but for the PTVs and most OARs it seems that having a slightly
stronger lower objective (100-125) as compared to the upper objective is beneficial.
Again, the differences are small and the optimal priorities need to be determined on
a case-by-case basis.
The weights of the dose-volume objectives on a structure are normalized by dividing
them with the volume of the structure. As the cost of a dose-volume objective (Eq.
(5) in Section 4.2.1) is summed over all voxels of the structure, the normalization
is needed to render the objective’s apparent weight independent of the structure’s
volume. The weights of the spatial objectives are not normalized. Normalizing the
weights might help in finding priorities that work for most cases. However, it also
makes the spatial objectives’ weights depend on the volume that receives little or no
dose.
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Figure 14 – The RMSEs for case A after 100 iterations of optimization for varying
lower spatial objective priorities. The lower objective is set for PTV+10mm margin.
The different priorities are represented with different colors (cf. lengend on the right).
Figure 15 – The RMSEs for case B after 50 iterations of optimization for varying
lower spatial objective priorities. The lower objective is set for PTV + 10mm margin.
Here PTV denotes the union of PTV Low and PTV High. The different priorities are
represented with different colors (cf. lengend on the right)
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6 Plan conversion using spatial objectives
In the plan conversion use case the aim is to recreate an existing dose distribution
on another treatment machine. As the machines may be dosimetrically different, the
best result is achieved by re-optimizing the plan for the new machine.
In this Section the spatial objectives will be evaluated as a method for performing
plan conversion. The resulting plans will be compared to the original plans and those
produced by the DVH based plan converter (Varian Medical Systems, Inc [2015b])
currently used in Eclipse (later referred to as Current). The quality of the converted
plans is analyzed using the criteria discussed in Section 3.
6.1 Test set of treatment plans
A set of 18 clinical plans provided by Varian was used for testing the plan conversion.
Each plan corresponds to a different patient. Varian’s clinical personnel has confirmed
that the plans are clinically acceptable. Ten of the patients are prostate cases and
eight are head and neck (HN) cases.
In all prostate cases (P1 - P10) the clinically relevant structures are a single PTV,
bladder, rectum, and femoral heads (left and right). The prescriptions range from
66.6Gy to 79.2Gy.
The head and neck cases (HN1 - HN8) are more complex, consisting of one to three
targets, and many OARs. The targets have prescriptions ranging from 52Gy to
70Gy.
The original plans have been optimized for Varian’s TrueBeam or C-series machines
using a 120 leaf MLC (Millennium 120). The prostate plans use energy of 18MV
and the head and neck cases use 6MV.
6.2 Test setup
A Varian C-series clinac is used as the target machine to which the plans will be
converted. It is capable of delivering an IMRT treatment with the same beam
configuration as defined in the original plan. The beam configuration has a large
impact on the spatial distribution of the dose, so a differing beam configuration
would need special handling with regards to the spatial objective. Moreover, in most
cases the target machine can provide the exactly same beam configuration as the
original machine. Thus only cases where beam configuration remains constant are
considered here.
To guarantee that there are differences between the original machine and the target
machine, an 80 leaf MLC (Millennium 80) is used for the target machine. Compared to
Millennium 120 the Millennium 80 has lower resolution which restricts the modulation
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it is capable of providing. Thus, the target machine cannot produce exactly the
original dose. For all converted plans the energy is set to 6MV, producing dosimetric
variation in the prostate case. Beam, couch, and collimator angles were kept the
same but the converters were allowed to change the field sizes.
The DVH based plan converter tool was used to convert each plan for the target
machine in order to create a set of benchmark plans. Only structures deemed
clinically relevant were selected to be included in the conversion. The OARs were set
as avoidance structures in Eclipse, and the target(s) were marked as PTV structures.
The number of fractions for the converted plan was set to match with the original
plan so that the dose levels are comparable. A stopwatch was used to time the actual
conversion, i.e., excluding the structure selection and the final dose calculation.
A new procedure that utilizes spatial objectives for plan conversion was created based
on the results in Section 5. The procedure converts plans using an ESAPI script and
a few manual steps in Eclipse. The manual part was required for the parameters
that are currently not exposed through the ESAPI. This conversion method is later
referred to as Spatials. The plan conversion works as follows
1. Create a copy of a source plan with the target treatment machine and beams
correctly set up.
2. Set the upper spatial objective (corresponding to dose from the source plan)
for whole body.
3. Set the lower spatial objective (corresponding to dose from the source plan)
for the volume covered by targets extended by a 10mm margin.
4. Optimize with automatic stop on convergence.
5. Perform leaf motion calculation and dose calculation.
6. Continue optimization with the achieved dose as intermediate dose, using again
automatic stop on convergence.
7. Perform final leaf motion calculation and dose calculation.
For the lower spatial objective, a priority of 165 was used, while the upper objective’s
priority was set to 100. The relative priorities of the spatial objectives used here
differ from the ones suggested in Section 5.3.6. Having only slightly more priority
to the lower objective works well when the dose distribution is reachable. Here,
however, the exact dose cannot be reached due to the target machine having an
inferior MLC when compared to the original machine, and the whole-body upper
spatial objective will restrict the dose quite heavily. To prevent underdosage, the
lower spatial objective needs higher priority.
The optimizer algorithm uses a faster and less accurate dose calculation than the final
dose calculation, which results in a difference between the dose received produced the
optimizer and the one from the final dose calculation. As explained in Section 4.1, the
difference can be reduced by using an intermediate dose calculation. Here especially
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the leaf motion calculation seemed to affect the resulting dose and doing a full leaf
motion calculation and dose calculation as the intermediate dose seemed to improve
the results. In some cases the intermediate dose also helps to improve the dose
homogeneity for the target and to reduce the OAR doses.
First tests of the conversion showed very high dose hot spots in some HN cases. The
reason was that the volume for which the lower objective was set went over the body
volume. To reduce the hot spots, the margin in the volume for which the lower
objective was set was retracted by 2mm from the body outline. The whole target
volume was still included in the lower objective volume.
After the converted plans were generated, they were normalized such that the PTV
𝐷𝑚𝑒𝑎𝑛 is the same for the original and the two converted plans. For the plans
that have multiple PTVs the one with highest dose prescription was used for the
normalization. The normalization was done in order to make the plans comparable.
Different normalization point would yield slightly different results.
Another ESAPI script was used to collect predefined metrics from each plan. For
prostate and HN cases different dose-volume metrics were specified based on Emami
[2013]. The metrics are meant to indicate the clinically relevant points for comparison.
The main criteria used is 𝐷𝑚𝑎𝑥 for serial organs and 𝐷𝑚𝑒𝑎𝑛 for parallel organs. In
addition to 𝐷𝑚𝑎𝑥 also 𝐷2% is reported according to the ICRU83 recommendation.
The original plans have aimed for a homogeneous dose to targets. To see if the
homogeneity is preserved in the conversion, the homogeneity index [see Eq. (2),
Section 3.4] was calculated for each target.
Additional criteria include 𝐷𝑚𝑎𝑥 and 𝐷𝑚𝑒𝑎𝑛 for the body structure to confirm that the
overall dose level stays approximately the same and to make sure that no points with
very high dose are produced outside the targets. Also the HOT measure (Section 3.4)
is reported. The RMSE metric is calculated for all voxels where the dose is significant
(> 10% of prescribed dose) in the converted plan. The low-dose regions are mostly
scattered dose and can be assumed to be similar in the original and in the converted
plans.
6.3 Plan conversion for prostate cases
The metrics that were used for the OARs in the prostate cases are listed in Table 7.
For the PTVs, the near-min, near-max, and max doses are reported, as well as the
homogeneity index. 𝐷𝑚𝑒𝑎𝑛 and 𝐷𝑚𝑎𝑥 were also calculated for the body structure, as
well as the hot spots outside target volume and the root mean square error. In all
of the converted plans the overall maximum dose was inside the PTV, so the body
𝐷𝑚𝑎𝑥 is not reported.
A summary of the results is shown in Table 8. The average values of the metrics
in the original plans are shown for reference. For the converted plans, the mean
differences are shown, as well as the maximum differences. For PTV 𝐷98% a high
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Table 7 – Dose-volume metrics for the prostate cases, based on Emami [2013]. The
goals are indicative only.
Organ at Risk Metric Goal
Femoral Heads 𝐷𝑚𝑎𝑥[𝐺𝑦] 52
Bladder 𝑉65𝐺𝑦[%] 50
Bladder 𝑉70𝐺𝑦[%] 35
Rectum 𝑉50𝐺𝑦[%] 50
Rectum 𝑉65𝐺𝑦[%] 35
value is preferable, but for all other metrics a lower value is better. The converted
plans have been normalized to have the same 𝐷𝑚𝑒𝑎𝑛 for the PTV as in the original
plan. The average amounts of normalization were 1.12%± 1.01% and 0.60%± 0.26%
(i.e., the dose levels were scaled up by about 1%) for the plans converted with the
Spatials and Current methods, respectively.
Table 8 – The results of the plan conversions for the prostate cases. First the metrics’
average values and standard deviations for the original plans are shown. For the
converted plans, the average and maximum differences are shown. For PTV 𝐷98% a
high value is preferable, otherwise a lower value is better. Fem. Head, L and Fem.
Head, R stand for left and right femoral heads, respectively.
Structure Metric Original ΔSpatials ΔCurrent
Mean 𝜎 Mean max Mean max
PTV 𝐷98%[𝐺𝑦] 73.80 6.25 -1.63 -4.23 -1.63 -2.50
PTV 𝐷2%[𝐺𝑦] 76.88 6.39 1.10 3.65 0.52 0.97
PTV 𝐷𝑚𝑎𝑥[𝐺𝑦] 77.64 6.01 2.58 7.34 1.40 2.55
PTV HI 0.04 0.01 0.04 0.06 0.03 0.05
Fem. Head, L 𝐷𝑚𝑎𝑥[𝐺𝑦] 46.13 4.55 2.02 9.14 1.97 12.27
Fem. Head, R 𝐷𝑚𝑎𝑥[𝐺𝑦] 41.92 7.41 -2.47 -0.57 0.76 5.71
Bladder 𝑉65𝐺𝑦[%] 21.62 18.06 -0.01 0.89 -0.55 0.78
Bladder 𝑉70𝐺𝑦[%] 5.83 9.32 0.22 1.69 0.31 2.97
Rectum 𝑉50𝐺𝑦[%] 20.19 10.94 1.10 1.90 2.40 5.55
Rectum 𝑉65𝐺𝑦[%] 10.92 5.75 -0.23 0.53 0.01 0.78
Body 𝐷𝑚𝑒𝑎𝑛[𝐺𝑦] 4.05 1.38 0.34 0.46 0.50 0.83
HOT [𝑐𝑐] 18.25 8.68 -3.39 -1.01 7.86 22.84
RMSE [𝑝𝑝] 5.82 7.60 8.18 10.32
Compared to the original plans, the Spatials conversion produces slightly worse
plans. This is expected, as the target machine is not capable of producing the dose
distribution of the source plan. On average, the conversion results in significantly
worse PTV dose homogeneity that is visible in the homogeneity index and PTV’s
𝐷2%, 𝐷98% and 𝐷𝑚𝑎𝑥. The average difference is also significant for left femoral head’s
𝐷𝑚𝑎𝑥, where the converted plans are worse than the originals. Interestingly, the
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converted plans have smaller HOT volume than the original plans. This may be
related to having also smaller PTV 𝐷98%. The definition of HOT is the volume
outside target with > 100% dose. Having a slightly reduced 𝐷98% for the PTV allows
the optimizer to reduce the dose in other parts of the body below the prescription
dose, thus reducing the HOT volume. For other metrics, the average differences are
small or show improvement in the converted plan.
The maximum differences in the metrics between the plans converted with the Spatials
method indicate the same behavior. The conversion has problems with the PTV
dose homogeneity, resulting in very 𝐷98%, 𝐷2% and 𝐷𝑚𝑎𝑥 for the PTV in some cases.
The metrics calculated from the converted plans were also compared against the
goals in Table 7. Mostly the goals were achieved. The 𝑉65𝐺𝑦 ≤ 50% goal was not
achieved in one case, but in that case the volume was actually even higher in the
original plan. The goal of 𝐷𝑚𝑎𝑥 ≤ 52Gy for the left femoral head was exceeded in
three cases. In two of those the converted plan had significantly higher dose than
the original plan. The conversion made with the Current method resulted in even
higher dose for the left femoral head in two of the three cases.
Compared to the Current method, the Spatials method seems to produce similar or
better plans in terms of everything else except the PTV near-maximum and maximum
doses. Especially the RMSE metric is clearly smaller for the plans converted using
the spatial objectives, meaning that the spatial objectives do guide the optimizer to
a solution that is on average closer to the original dose distribution. An example
comparison of DVHs is shown in Figure 16.
Figure 16 – A comparison of the DVHs for P1. Triangles mark the original plan,
squares the Spatials conversion and circles the Current conversion. PTV is red, blue
and cyan are left and right femoral heads, and yellow and brown are for bladder and
rectum.
Unlike the Spatials method, the Current method results in a significant increase in
the volume of hot spots outside target. This occurs also in cases where the Spatials
conversion results in higher 𝐷98% for the PTV. Since the DVH based plan converter
only considers the structures selected for the conversion (in this case the PTV, OARs
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and body), it allows higher doses in the tissue not covered by the PTV or OARs.
The upper spatial objective prevents the dose from increasing in any part of the
body, leading to less hot spots in the Spatials method.
Three of the ten cases are shown in Appendix A. Tables A1 and A3 show cases where
the Spatials conversion produced overall better plans than the Current method. A
case where the Spatials method resulted in significantly worse plan (due to low PTV
homogeneity) is shown in Table A2.
To summarize, it seems that the conversion method based on the spatial objectives
produces overall more similar dose distribution, but has problems with PTV’s near-
minimum, near-maximum and maximum doses. Excluding the PTV homogeneity the
plans produced with the Spatials conversion are, according to the criteria used here,
of at least as high clinical quality as the plans produced with the Current conversion
method.
In addition to the quality of the conversion, the time it takes is also of interest.
The average times for the prostate cases are shown in Table 9. Excluding the final
dose calculation (that is common to both methods) and the structure selection step
(required by the Current method), the Spatials method takes almost twice as long
as the Current method. Still, the Spatials method takes approximately 2min which
should be acceptable in practice. It should be noted that the Spatials method is
implemented through ESAPI. Implementing it natively as a part of Eclipse would
likely make it faster. There is also much room for optimization in the conversion
process if speed is deemed important.
The Spatials method uses less than half of the time for optimization. The rest goes for
setting up the conversion and performing the intermediate dose calculation. Without
the intermediate dose calculation and second optimization, the Spatials conversion
would be faster than the Current method, but the quality of the conversion would
suffer.
Table 9 – The running time of the converters, averaged over the ten prostate cases.
The first row corresponds to the DVH based converter currently used in Eclipse. The
second row is the time the Spatials conversion takes. The last four rows show a
break-down of the Spatials conversion. Also standard deviations are shown.
Mean [s] Iterations
Current 60± 20
Spatials 105± 14
Setup 31± 6
1st run 23± 4 20± 2
Dose calc 31± 4
2nd run 20± 4 11± 0
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6.4 Plan conversion for head and neck cases
The metrics that were used for the HN patients’ OARs are listed in Table 10. For
the PTVs, the near-min, near-max, and max doses are reported, as well as the
homogeneity index. The plans had one to three targets with differing dose levels.
Here PTV High denotes for each plan the target with the highest dose, PTV Med
the target with the second highest dose (if the plan has two or three PTVs), and
PTV Low denotes the target with the lowest dose prescription (if the plan has three
PTVs). The converted plans have been normalized to have the same 𝐷𝑚𝑒𝑎𝑛 for the
PTV High as in the original plan. For PTV Med the 𝐷𝑚𝑒𝑎𝑛 is also reported. Only
one case had three PTVs, so the third one (PTV Low) is not listed in the averaged
results. For the body structure 𝐷𝑚𝑒𝑎𝑛, 𝐷𝑚𝑎𝑥, and hot spots outside target were
calculated. Also the root mean square error is reported. The average amounts of
normalization were −1.04%± 0.36% and −1.14%± 0.62% (i.e., the dose levels were
scaled down by about 1%) for the plans converted with the Spatials and Current
methods, respectively.
Table 10 – Dose-volume metrics for the head and neck cases, based on Emami [2013].
The goals are indicative only.
Organ at Risk Metric Goal
Brain 𝐷𝑚𝑎𝑥[𝐺𝑦] 60
Brainstem 𝐷𝑚𝑎𝑥[𝐺𝑦] 64
Chiasm 𝐷𝑚𝑎𝑥[𝐺𝑦] 50
Ear 𝐷𝑚𝑒𝑎𝑛[𝐺𝑦] 45
Esophagus 𝐷𝑚𝑒𝑎𝑛[𝐺𝑦] 34
Eye 𝐷𝑚𝑎𝑥[𝐺𝑦] 50
Larynx 𝐷𝑚𝑒𝑎𝑛[𝐺𝑦] 44
Mandible 𝐷𝑚𝑎𝑥[𝐺𝑦] 70
Optic Nerve 𝐷𝑚𝑎𝑥[𝐺𝑦] 50
Parotid 𝐷𝑚𝑒𝑎𝑛[𝐺𝑦] 20
Spinal Cord 𝐷𝑚𝑎𝑥[𝐺𝑦] 50
The results for the head and neck cases are summarized in Table 11. Again the plans
converted with the Spatials method have mostly worse metrics than the original ones,
as is to be expected. On average the plans converted with the Spatials have slightly
worse PTV dose homogeneity on both the high-dose PTV and the medium-dose
PTV, resulting in a lower 𝐷98% and a higher 𝐷2%, but the difference is smaller than
in the prostate cases. The 𝐷𝑚𝑎𝑥 of the high dose PTV is still on average significantly
higher than in the original plans.
In one case, the PTV High’s 𝐷𝑚𝑎𝑥 is almost 10Gy above the original plan, and one
case resulted in 5Gy higher 𝐷𝑚𝑎𝑥. In both cases there is a hot spot inside the PTV
High close to the body surface. This suggests that the lower spatial objective causes
the optimizer to try to increase the dose to the voxels near the body outline, but due
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Table 11 – The results of the plan conversions of the prostate cases. First the metrics’
average values and standard deviations for the original plans are shown. For the
converted plans, the average and maximum differences are shown. For PTV 𝐷98% a
high value is preferable, otherwise a lower value is better. For chiasm, eyes and optic
nerves the doses were insignificant (< 10Gy) and thus they are not shown here. PTV
High means for each patient the PTV with the highest dose prescription, and PTV
Med the second highest. Only one patient had three PTVs so the third one (PTV Low)
is not included.
Structure Metric Original ΔSpatials ΔCurrent
Mean 𝜎 Mean max Mean max
PTV High 𝐷98%[𝐺𝑦] 62.74 4.89 -0.49 -0.87 -0.97 -1.35
PTV High 𝐷2%[𝐺𝑦] 68.81 5.41 0.80 1.26 0.83 1.11
PTV High 𝐷𝑚𝑎𝑥[𝐺𝑦] 71.00 5.58 3.76 9.89 1.18 2.63
PTV High HI 0.09 0.02 0.02 0.03 0.03 0.04
PTV Med 𝐷98%[𝐺𝑦] 55.70 7.49 -0.56 -0.92 -0.61 -1.71
PTV Med 𝐷2%[𝐺𝑦] 61.93 8.24 0.71 1.22 0.99 1.68
PTV Med 𝐷𝑚𝑎𝑥[𝐺𝑦] 59.08 7.72 0.06 0.23 0.43 0.85
PTV Med 𝐷𝑚𝑒𝑎𝑛[𝐺𝑦] 64.67 8.69 1.62 2.93 1.90 3.99
PTV Med HI 0.11 0.03 0.02 0.04 0.03 0.05
Brain 𝐷2%[𝐺𝑦] 20.17 17.71 -0.34 0.95 1.60 6.10
Brain 𝐷𝑚𝑎𝑥[𝐺𝑦] 38.21 25.81 0.07 2.95 0.48 4.29
Brainstem 𝐷2%[𝐺𝑦] 19.29 15.24 -0.11 1.54 -0.47 1.36
Brainstem 𝐷𝑚𝑎𝑥[𝐺𝑦] 23.01 16.98 0.07 3.45 0.57 5.02
Ear, L 𝐷𝑚𝑒𝑎𝑛[𝐺𝑦] 10.09 11.76 0.82 1.95 -0.93 0.13
Ear, R 𝐷𝑚𝑒𝑎𝑛[𝐺𝑦] 5.15 3.72 0.83 1.50 0.24 1.29
Esophagus 𝐷𝑚𝑒𝑎𝑛[𝐺𝑦] 34.49 16.60 0.62 2.45 0.30 2.01
Larynx 𝐷𝑚𝑒𝑎𝑛[𝐺𝑦] 35.01 19.55 1.21 2.79 0.68 1.71
Mandible 𝐷2%[𝐺𝑦] 61.49 10.97 0.47 1.28 0.54 3.53
Mandible 𝐷𝑚𝑎𝑥[𝐺𝑦] 66.31 9.42 1.27 6.03 0.07 4.07
Parotid, L 𝐷𝑚𝑒𝑎𝑛[𝐺𝑦] 22.12 20.72 0.97 2.24 0.33 0.84
Parotid, R 𝐷𝑚𝑒𝑎𝑛[𝐺𝑦] 15.00 17.72 1.25 2.66 1.25 2.62
Spinal Cord 𝐷2%[𝐺𝑦] 35.27 2.35 -0.22 2.35 1.70 4.37
Spinal Cord 𝐷𝑚𝑎𝑥[𝐺𝑦] 37.22 2.65 0.07 1.54 2.92 8.54
Body 𝐷𝑚𝑎𝑥[𝐺𝑦] 71.04 5.61 3.72 9.89 1.57 5.77
Body 𝐷𝑚𝑒𝑎𝑛[𝐺𝑦] 10.46 2.53 -0.63 0.21 -0.28 1.20
Body HOT [𝑐𝑐] 34.09 34.29 -1.95 1.61 22.47 49.15
RMSE [𝑝𝑝] 0.00 0.00 3.85 6.01 8.00 10.14
to dose build-up effect it ends up creating a hot spot inside the PTV. To prevent
this kind of problems the margin used for the targets when setting the lower spatial
objective volume was retracted 2mm from the border of the body structure. The
problem may be caused by the 2mm being not enough, or it may happen because
all of the target volume was still included in the lower objective.
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In these cases the Spatials conversion results in better target homogeneity than the
Current conversion method for both targets. Also the 𝐷𝑚𝑒𝑎𝑛 for PTV Med is closer
to that of the original plans when using the Spatials method. Out of 14 OAR metrics,
seven have smaller average difference when using the Spatials method and the other
seven when using the Current method. Notably the Spatials plans show smaller
increases for brain and spinal cord. The plans converted with the Spatials method
have similar volume of hot spots outside target when compared to the original plans,
while the Current conversion increases the volume significantly. The RMSE metric
is smaller for the Spatials method, meaning that the dose distributions of the plans
converted using the spatial objectives are closer to those of the original plans.
The values calculated for the metrics were also compared against the goals in Table 10.
The plans created with the Spatials conversion stayed inside the goals in all the cases
where the original plan was inside the goals. However, in three cases the Spatials
conversion further deteriorated two or three metrics that were already outside of the
clinical goal. These metrics were the 𝐷𝑚𝑎𝑥 for mandible and 𝐷𝑚𝑒𝑎𝑛 for esophagus
and parotids.
The calculated metrics for three of the eight cases are shown in Appendix B. A case
where the Spatials method resulted in significantly worse plan (due to a hot spot
inside the high-dose PTV) is shown in Table B1. Table B2 shows a case where the
Spatials conversion produced overall better plan than the Current method. Table B3
is an example of a case where the conversion worsened a metric that is already outside
of the goal.
To summarize, in most cases the Spatials conversion seemed to result in a plan that
is overall closer to the original plan. In these cases it also results in better target
doses, excluding the two cases with hot spots inside the PTV High. The values for
the OAR metrics are similar to those of the plans produced with the DVH based
plan converter.
Table 12 – The running time of the converters, averaged over the eight HN cases. The
first row corresponds to the DVH based converter currently used in Eclipse. The second
row is the time the Spatials conversion takes. The last four rows show a break-down of
the Spatials conversion.
Mean (s) STD Iterations
Current 48 13
Spatials 139 30
Setup 24 4
1st run 44 14 33± 7
Dose calc 40 9
2nd run 31 8 15± 2
Table 12 shows the conversion times for the head and neck cases. Interestingly the
Current conversion is faster than in the prostate cases, but the Spatials conversion
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is significantly slower. Although the difference is now more notable, the Spatials
conversion still takes only about 2.5min, which is acceptable in practice.
The increase in running time for the Spatials method compared to the prostate cases
is mostly due to the optimizer performing more iterations before convergence. For
the HN cases there is also more variation in the number of iterations for both the
first and the second optimization runs.
6.5 Additional remarks for further research
Other informal tests were done in addition to the results presented here. The usage
of dose-volume objectives in addition to the spatial objectives seemed to result in
slightly better values for the metrics, and is something that could be studied further.
The objectives were set for the targets (an exact line objective and high priority upper
and lower point objectives) and organs at risk (upper line objectives). Especially the
upper and lower objectives for the targets improved dose homogeneity significantly.
While the spatial objectives are able to direct the optimizer towards the original dose,
the dose-volume objectives help the optimizer when the spatial objectives cannot be
satisfied.
Using the same dose-volume objectives was also tested without spatial objectives.
With no objective affecting the rest of the body, the optimizer achieved greatly
improved OAR sparing but created hot spots on the normal tissue. The resulting
plans differed greatly from the original plans and were clinically unacceptable. This
confirms that the role of the spatial objectives is significant even if both spatial and
dose-volume objectives are used.
The results reported here were done with a 10mm margin around the targets for the
lower spatial objective. Also 5mm and 20mm margins were tested. The differences
in the resulting values for the metrics were small. The optimal margin depends on
the case and the metric used to evaluate the results.
One of converted plans was optimized for 1000 iterations to see if the local optima
effect discussed in Section 5.2 is visible in the plan conversion. The additional
iterations did not improve the results, suggesting that the local optima is a problem
only in the case where a zero-cost global optimum exists.
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7 Conclusions
The aim of this Thesis was to explore the usage of spatial objectives in radiation
therapy treatment planning, focusing on the plan conversion use case. The empirical
work was divided into two parts: in the first part the behavior of the spatial objectives
was analyzed (Section 5) and then the usage of the spatial objectives in the context
of plan conversion was tested (Section 6).
The analysis in Section 5 shows that the spatial objectives do work as a means of
directing the optimizer towards a wanted dose distribution. Compared to using
dose-volume objectives, the spatial objectives resulted in significantly lower RMSE
between the targeted and the achieved doses. Combining the spatial objectives with
the dose-volume objectives yielded even lower error. Further testing indicated that
in order to achieve the best results, the lower objective should be set at least for the
target structures plus an additional margin, otherwise the near-border regions of the
target will easily get underdosed. When the objective dose was achievable, setting
the lower spatial objective for the whole body was found to be plausible. Giving
the lower objective slightly higher priority than the upper objective was found to
improve the results.
The results of the plan conversion tests indicate that the spatial objectives are useful
in the process. In many cases the conversion utilizing spatial objectives produced
better results than the converter used currently in Eclipse, and only in a few cases
did the conversion produce plans that are significantly worse than the original plan
with regards to one or more of the specified criteria. When compared against the
DVH based plan conversion, the spatial objectives resulted in all cases in a dose
distribution that is overall significantly closer to the dose distribution of the original
plan. The conversion was somewhat slower than the current converter, but there is
room for improvement in the speed.
In few cases, the conversion using the spatial objectives resulted in clinically unac-
ceptable results. Using for example dose-volume objectives for the targets in addition
to the spatial objectives would probably help to improve the target homogeneity.
The problem of hot spots close to the body structure’s border can probably be solved
by adjusting the volume for which the lower spatial objective is set.
The tests performed here raise many new questions. In Section 5 it was observed that
when optimizing for an exact dose distribution, the gradient search got stalled and
achieved only small improvements after reaching a good solution, until an internal
mechanism allowed it to perform longer jumps in further improve the solution. The
reason may be that the optimization landscape has a local optimum or a narrow
valley through which the gradient search must pass. Further studies of the optimizer
could improve the results. Also, using different optimization algorithms instead or
in addition to the gradient search might allow the optimizer to escape the possible
local minima and reach the global minimum.
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Regarding the plan conversion use case, this Thesis considered only IMRT to IMRT
conversions, where the beam configuration was kept unchanged. There may be cases
where a VMAT plan needs to be converted to IMRT. In some special cases also an
IMRT to VMAT conversion might be useful. In these cases the beam geometry is
very different between the original plan and the converted plan. In these cases having
an upper spatial objective with constant weight for the whole body probably does
not work. For example, when converting from VMAT to IMRT, the normal tissue
volume radiated by the IMRT beams will inevitably have higher dose when compared
to the VMAT plan, causing very high costs for the upper objective and leading to
underdosage. A potential solution would be to accompany the objective matrices
with matching weight matrices so that the user could specify which structures or
other volumes are most important.
The results of the conversion depend on the priorities of the objectives. The priorities
used here were selected based on the tests in Section 5 and then adjusted to fit the
plan conversion case. In order to prevent underdosage the lower spatial objective had
to be given a higher priority relative to the upper spatial objective than warranted by
the test cases. The selected priorities seemed to work well enough for the cases tested
in Section 6, but they may not be universally applicable. An adaptive optimization
changing the priorities of the objectives based on the progress of the optimizer could
make the priorities more robust.
This Thesis focused on using the spatial objectives to recreate a realistic dose
distribution. Regarding the dose painting method, i.e., prescribing different levels
of radiation into different voxels of the target based on e.g., MRI images, further
studies are needed.
The results of this thesis can be used to improve the radiation therapy treatment
planning and the treatments received by the patients.
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A Plan Conversion tests: Prostate
Table A1 – Results for P1. In this case, the Spatials conversion produces a plan that
is superior to the plan produced with the Current method in all areas except the PTV
maximum dose.
Structure Metric Original Spatials Δ Current Δ
Δ Δ
PTV 𝐷98%[𝐺𝑦] 67.41 66.40 -1.01 65.77 -1.64
PTV 𝐷2%[𝐺𝑦] 70.83 71.29 0.46 71.35 0.52
PTV 𝐷𝑚𝑎𝑥[𝐺𝑦] 71.81 73.48 1.67 73.03 1.21
PTV HI 0.05 0.07 0.02 0.08 0.03
Fem. Head, L 𝐷𝑚𝑎𝑥[𝐺𝑦] 49.50 47.42 -2.09 49.78 0.27
Fem. Head, R 𝐷𝑚𝑎𝑥[𝐺𝑦] 50.55 48.26 -2.29 56.26 5.71
Bladder 𝑉65𝐺𝑦[%] 27.33 27.46 0.13 27.36 0.03
Bladder 𝑉70𝐺𝑦[%] 2.41 4.10 1.69 5.38 2.97
Rectum 𝑉50𝐺𝑦[%] 26.39 27.63 1.24 31.24 4.85
Rectum 𝑉65𝐺𝑦[%] 9.71 9.30 -0.41 9.50 -0.22
Body 𝐷𝑚𝑒𝑎𝑛[𝐺𝑦] 5.12 5.40 0.28 5.57 0.45
HOT [𝑐𝑐] 28.02 23.45 -4.57 42.07 14.05
RMSE [𝑝𝑝] 5.05 5.05 7.73 7.73
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Table A2 – Results for P2. In this case the Spatials conversion results in significant
increase in the homogeneity index due to a very low 𝐷98%. The values for bladder are
very small (< 2%) and thus not reported.
Structure Metric Original Spatials Δ Current Δ
PTV 𝐷98%[𝐺𝑦] 81.29 77.05 -4.23 79.94 -1.34
PTV 𝐷2%[𝐺𝑦] 83.83 84.32 0.49 84.30 0.47
PTV 𝐷𝑚𝑎𝑥[𝐺𝑦] 84.17 85.17 0.99 85.28 1.11
PTV HI 0.03 0.09 0.06 0.05 0.02
Fem. Head, L 𝐷𝑚𝑎𝑥[𝐺𝑦] 45.42 50.20 4.78 48.73 3.31
Fem. Head, R 𝐷𝑚𝑎𝑥[𝐺𝑦] 33.81 33.24 -0.57 38.61 4.80
Bladder 𝑉65𝐺𝑦[%] 1.91 1.74 -0.17 1.77 -0.15
Bladder 𝑉70𝐺𝑦[%] 1.54 1.37 -0.18 1.42 -0.12
Rectum 𝑉50𝐺𝑦[%] 8.28 10.18 1.90 10.16 1.88
Rectum 𝑉65𝐺𝑦[%] 4.37 4.73 0.36 5.16 0.78
Body 𝐷𝑚𝑒𝑎𝑛[𝐺𝑦] 1.80 2.05 0.24 2.12 0.32
HOT [𝑐𝑐] 36.76 28.14 -8.62 39.80 3.03
RMSE [𝑝𝑝] 7.60 7.60 10.32 10.32
Table A3 – Results for P3. The plan produced with the Spatials method is superior
to the plan produced with the Current method in all metrics except the bladder’s
𝑉65𝐺𝑦, where both converted plans have lower volume than the original plan.
Structure Metric Original Spatials Δ Current Δ
PTV 𝐷98%[𝐺𝑦] 66.61 65.39 -1.23 64.96 -1.66
PTV 𝐷2%[𝐺𝑦] 69.28 69.88 0.60 70.01 0.73
PTV 𝐷𝑚𝑒𝑎𝑛[𝐺𝑦] 67.94 67.94 0.00 67.94 0.00
PTV 𝐷𝑚𝑎𝑥[𝐺𝑦] 70.64 72.39 1.75 71.83 1.20
PTV HI 0.04 0.07 0.03 0.07 0.04
Fem. Head, L 𝐷𝑚𝑎𝑥[𝐺𝑦] 54.59 53.70 -0.89 54.71 0.12
Fem. Head, R 𝐷𝑚𝑎𝑥[𝐺𝑦] 48.37 45.56 -2.81 49.18 0.81
Bladder 𝑉65𝐺𝑦[%] 56.63 55.90 -0.73 54.01 -2.62
Bladder 𝑉70𝐺𝑦[%] 0.00 0.47 0.47 0.95 0.95
Rectum 𝑉50𝐺𝑦[%] 34.01 35.06 1.05 39.56 5.55
Rectum 𝑉65𝐺𝑦[%] 15.18 14.01 -1.18 13.95 -1.24
Body 𝐷𝑚𝑎𝑥[𝐺𝑦] 70.64 72.39 1.75 71.83 1.20
Body 𝐷𝑚𝑒𝑎𝑛[𝐺𝑦] 5.52 5.96 0.43 6.35 0.83
RMSE [𝑝𝑝] 0.00 5.16 5.16 8.58 8.58
HOT [𝑐𝑐] 20.31 13.81 -6.50 30.22 9.92
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B Plan Conversion tests: Head and Neck
Table B1 – Results for HN1. This is one of the two cases where the Spatials method
resulted in a clinically unacceptable hot spot inside the PTV High. The plan converted
with the Current method results has smaller 𝐷𝑚𝑎𝑥 for the PTV High. Interestingly,
its body 𝐷𝑚𝑎𝑥 is higher than the PTV High 𝐷𝑚𝑎𝑥, meaning that the highest dose goes
outside the targets.
Structure Metric Original Spatials Δ Current Δ
PTV High 𝐷98%[𝐺𝑦] 64.70 63.83 -0.87 63.35 -1.35
PTV High 𝐷2%[𝐺𝑦] 69.74 70.90 1.15 70.85 1.10
PTV High 𝐷𝑚𝑒𝑎𝑛[𝐺𝑦] 67.52 67.52 67.52
PTV High 𝐷𝑚𝑎𝑥[𝐺𝑦] 71.33 81.22 9.89 73.64 2.31
PTV High HI 0.07 0.10 0.03 0.11 0.04
Brain 𝐷𝑚𝑎𝑥[𝐺𝑦] 1.02 1.19 0.17 1.18 0.16
Brainstem 𝐷2%[𝐺𝑦] 0.83 1.05 0.23 1.04 0.21
Brainstem 𝐷𝑚𝑎𝑥[𝐺𝑦] 1.01 1.22 0.21 1.21 0.20
Chiasm 𝐷𝑚𝑎𝑥[𝐺𝑦] 0.23 0.33 0.10 0.33 0.10
Ear, L 𝐷𝑚𝑒𝑎𝑛[𝐺𝑦] 0.36 0.46 0.11 0.45 0.10
Ear, R 𝐷𝑚𝑒𝑎𝑛[𝐺𝑦] 0.35 0.44 0.09 0.43 0.08
Esophagus 𝐷𝑚𝑒𝑎𝑛[𝐺𝑦] 64.37 64.22 -0.14 64.94 0.57
Eye, L 𝐷2%[𝐺𝑦] 0.37 0.39 0.02 0.37 0.00
Eye, L 𝐷𝑚𝑎𝑥[𝐺𝑦] 0.38 0.54 0.16 0.52 0.14
Eye, R 𝐷2%[𝐺𝑦] 0.37 0.36 -0.01 0.35 -0.02
Eye, R 𝐷𝑚𝑎𝑥[𝐺𝑦] 0.38 0.50 0.12 0.47 0.09
Larynx 𝐷𝑚𝑒𝑎𝑛[𝐺𝑦] 67.56 67.85 0.29 67.55 -0.00
Mandible 𝐷2%[𝐺𝑦] 47.71 48.99 1.28 47.35 -0.36
Mandible 𝐷𝑚𝑎𝑥[𝐺𝑦] 53.72 56.67 2.95 54.87 1.15
O. Nerve, L 𝐷𝑚𝑎𝑥[𝐺𝑦] 0.38 0.26 -0.11 0.26 -0.12
O. Nerve, R 𝐷𝑚𝑎𝑥[𝐺𝑦] 0.37 0.30 -0.07 0.30 -0.07
Parotid, L 𝐷𝑚𝑒𝑎𝑛[𝐺𝑦] 2.35 2.53 0.18 2.59 0.24
Parotid, R 𝐷𝑚𝑒𝑎𝑛[𝐺𝑦] 1.42 1.56 0.13 1.60 0.18
Spinal Cord 𝐷2%[𝐺𝑦] 36.60 35.86 -0.74 37.06 0.47
Spinal Cord 𝐷𝑚𝑎𝑥[𝐺𝑦] 38.50 39.30 0.80 43.36 4.86
Body 𝐷𝑚𝑎𝑥[𝐺𝑦] 71.33 81.22 9.89 77.10 5.77
Body 𝐷𝑚𝑒𝑎𝑛[𝐺𝑦] 8.36 7.96 -0.40 8.09 -0.26
RMSE [𝑝𝑝] 4.83 4.83 7.59 7.59
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Table B2 – Results for HN2. In this case the Spatials conversion resulted in better
values for almost all metrics when compared to the Current conversion. The only
clinically relevant exception is the 𝐷𝑚𝑎𝑥 for the PTV High. The RMSE values show
that of the two plans, the dose distribution of the plan created with the Spatials
conversion is significantly closer to the original dose distribution.
Structure Metric Original Spatials Δ Current Δ
PTV High 𝐷98%[𝐺𝑦] 58.28 57.84 -0.43 56.96 -1.32
PTV High 𝐷2%[𝐺𝑦] 63.45 64.43 0.97 64.40 0.94
PTV High 𝐷𝑚𝑒𝑎𝑛[𝐺𝑦] 61.55 61.55 61.55
PTV High 𝐷𝑚𝑎𝑥[𝐺𝑦] 64.60 68.26 3.67 67.23 2.63
PTV High HI 0.08 0.11 0.02 0.12 0.04
PTV Med 𝐷98%[𝐺𝑦] 50.38 49.93 -0.45 50.03 -0.35
PTV Med 𝐷2%[𝐺𝑦] 55.54 56.45 0.91 56.70 1.16
PTV Med 𝐷𝑚𝑎𝑥[𝐺𝑦] 53.32 53.35 0.03 54.06 0.74
PTV Med 𝐷𝑚𝑒𝑎𝑛[𝐺𝑦] 57.42 60.34 2.93 61.41 3.99
PTV Med HI 0.10 0.12 0.03 0.12 0.03
Brain 𝐷2%[𝐺𝑦] 26.19 25.79 -0.39 28.86 2.68
Brain 𝐷𝑚𝑎𝑥[𝐺𝑦] 48.43 51.39 2.95 52.73 4.29
Brainstem 𝐷2%[𝐺𝑦] 33.64 33.41 -0.23 35.00 1.36
Brainstem 𝐷𝑚𝑎𝑥[𝐺𝑦] 39.23 37.32 -1.91 44.25 5.02
Chiasm 𝐷2%[𝐺𝑦] 2.34 2.36 0.02 2.39 0.05
Chiasm 𝐷𝑚𝑎𝑥[𝐺𝑦] 2.42 2.44 0.02 2.47 0.05
Ear, L 𝐷𝑚𝑒𝑎𝑛[𝐺𝑦] 14.20 16.16 1.95 13.95 -0.25
Ear, R 𝐷𝑚𝑒𝑎𝑛[𝐺𝑦] 8.66 9.77 1.11 8.47 -0.19
Esophagus 𝐷𝑚𝑒𝑎𝑛[𝐺𝑦] 24.88 25.13 0.25 25.02 0.14
Eye, L 𝐷2%[𝐺𝑦] 1.56 1.58 0.02 1.66 0.10
Eye, L 𝐷𝑚𝑎𝑥[𝐺𝑦] 1.76 1.78 0.01 1.87 0.10
Eye, R 𝐷2%[𝐺𝑦] 1.59 1.62 0.02 1.53 -0.06
Eye, R 𝐷𝑚𝑎𝑥[𝐺𝑦] 1.73 1.76 0.03 1.66 -0.07
Larynx 𝐷𝑚𝑒𝑎𝑛[𝐺𝑦] 23.91 24.62 0.71 25.62 1.71
Mandible 𝐷2%[𝐺𝑦] 58.71 58.75 0.03 62.24 3.53
Mandible 𝐷𝑚𝑎𝑥[𝐺𝑦] 63.57 63.97 0.41 64.70 1.13
O. Nerve, L 𝐷2%[𝐺𝑦] 1.92 1.94 0.02 2.00 0.08
O. Nerve, L 𝐷𝑚𝑎𝑥[𝐺𝑦] 2.01 2.03 0.01 2.08 0.07
O. Nerve, R 𝐷2%[𝐺𝑦] 2.11 2.14 0.03 2.15 0.04
O. Nerve, R 𝐷𝑚𝑎𝑥[𝐺𝑦] 2.35 2.39 0.04 2.43 0.08
Parotid, L 𝐷𝑚𝑒𝑎𝑛[𝐺𝑦] 39.28 40.12 0.84 39.82 0.55
Parotid, R 𝐷𝑚𝑒𝑎𝑛[𝐺𝑦] 8.16 8.91 0.74 10.16 2.00
Spinal Cord 𝐷2%[𝐺𝑦] 34.54 33.05 -1.49 38.91 4.37
Spinal Cord 𝐷𝑚𝑎𝑥[𝐺𝑦] 38.13 36.21 -1.92 46.67 8.54
Body 𝐷𝑚𝑎𝑥[𝐺𝑦] 64.60 68.26 3.67 67.23 2.63
Body 𝐷𝑚𝑒𝑎𝑛[𝐺𝑦] 7.87 7.89 0.03 8.49 0.62
Body HOT [𝑐𝑐] 2.80 4.41 1.61 17.81 15.01
RMSE [𝑝𝑝] 2.19 2.19 8.09 8.09
52
Table B3 – Results for HN3. In this case the Spatials conversion resulted in an
significant increase in the 𝐷𝑚𝑎𝑥 for mandible. The goal for the mandible’s 𝐷𝑚𝑎𝑥 is
< 70Gy and the increase is significant. However, the Current conversion method
results also in a significant increase for the same metric. For 𝐷2% the increase is much
smaller.
Structure Metric Original Spatials Δ Current Δ
PTV High 𝐷98%[𝐺𝑦] 69.90 69.64 -0.26 69.36 -0.54
PTV High 𝐷2%[𝐺𝑦] 75.57 75.85 0.28 76.18 0.62
PTV High 𝐷𝑚𝑒𝑎𝑛[𝐺𝑦] 72.74 72.74 0.00 72.74 0.00
PTV High 𝐷𝑚𝑎𝑥[𝐺𝑦] 77.40 81.01 3.61 79.05 1.65
PTV High HI 0.08 0.09 0.01 0.09 0.02
PTV Med 𝐷98%[𝐺𝑦] 64.85 64.16 -0.69 64.40 -0.44
PTV Med 𝐷2%[𝐺𝑦] 71.61 71.55 -0.06 73.28 1.68
PTV Med 𝐷𝑚𝑎𝑥[𝐺𝑦] 68.44 68.18 -0.26 69.29 0.85
PTV Med 𝐷𝑚𝑒𝑎𝑛[𝐺𝑦] 74.45 74.59 0.13 76.69 2.24
PTV Med HI 0.10 0.11 0.01 0.13 0.03
Brain 𝐷2%[𝐺𝑦] 42.04 41.69 -0.35 48.14 6.10
Brain 𝐷𝑚𝑎𝑥[𝐺𝑦] 73.79 73.55 -0.24 72.22 -1.57
Brainstem 𝐷2%[𝐺𝑦] 16.18 17.73 1.54 17.43 1.25
Brainstem 𝐷𝑚𝑎𝑥[𝐺𝑦] 24.07 24.61 0.55 24.24 0.18
Chiasm 𝐷𝑚𝑎𝑥[𝐺𝑦] 2.40 3.01 0.61 3.39 1.00
Ear, L 𝐷𝑚𝑒𝑎𝑛[𝐺𝑦] 29.80 31.61 1.81 26.98 -2.82
Ear, R 𝐷𝑚𝑒𝑎𝑛[𝐺𝑦] 6.98 8.48 1.50 7.01 0.03
Esophagus 𝐷𝑚𝑒𝑎𝑛[𝐺𝑦] 35.93 36.90 0.98 34.18 -1.74
Eye, L 𝐷2%[𝐺𝑦] 2.33 2.98 0.65 3.08 0.74
Eye, L 𝐷𝑚𝑎𝑥[𝐺𝑦] 2.53 3.16 0.63 3.37 0.84
Eye, R 𝐷2%[𝐺𝑦] 1.67 2.43 0.76 2.03 0.36
Eye, R 𝐷𝑚𝑎𝑥[𝐺𝑦] 1.90 2.66 0.75 2.19 0.29
Larynx 𝐷𝑚𝑒𝑎𝑛[𝐺𝑦] 29.13 30.23 1.11 29.27 0.14
Mandible 𝐷2%[𝐺𝑦] 72.71 73.71 1.00 75.06 2.35
Mandible 𝐷𝑚𝑎𝑥[𝐺𝑦] 74.98 81.01 6.03 79.05 4.07
O. Nerve, L 𝐷𝑚𝑎𝑥[𝐺𝑦] 3.14 3.57 0.43 3.79 0.65
O. Nerve, R 𝐷𝑚𝑎𝑥[𝐺𝑦] 2.63 3.27 0.64 3.26 0.63
Parotid, R 𝐷𝑚𝑒𝑎𝑛[𝐺𝑦] 2.32 3.46 1.14 4.94 2.62
Spinal Cord 𝐷2%[𝐺𝑦] 36.25 35.54 -0.71 38.29 2.04
Spinal Cord 𝐷𝑚𝑎𝑥[𝐺𝑦] 38.47 39.41 0.94 43.83 5.36
Body 𝐷𝑚𝑎𝑥[𝐺𝑦] 77.40 81.01 3.61 79.05 1.65
Body 𝐷𝑚𝑒𝑎𝑛[𝐺𝑦] 10.16 10.37 0.21 10.96 0.80
Body HOT [𝑐𝑐] 76.20 69.84 -6.36 125.36 49.15
RMSE [𝑝𝑝] 3.98 9.94
